

Supporting Information

Enantioselective, Catalytic Fluorolactonization Reactions with a Nucleophilic Fluoride Source

Eric M. Woerly, Steven M. Banik, Eric N. Jacobsen*

Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford St., Cambridge, Massachusetts 02138, United States

*jacobsen@chem.harvard.edu

Table of contents:

I. General methods.....	SI-1
II. Synthesis of catalyst 2d	SI-2
III. Table 1. Optimization of reaction conditions.....	SI-3
IV. Preparation of substrates.....	SI-15
V. Table 2. Fluorolactonization of aryl substituted substrates.....	SI-34
VI. Table 3. Fluorolactonization of alkene substituted substrates.....	SI-60
VII. Scheme 2. Comparing electrophilic and nucleophilic fluorinating reagents.....	SI-74
VIII. Additional substrates.....	SI-79
IX. X-ray crystallographic data.....	SI-80
X. NMR spectra.....	SI-90

I. General methods


Materials. Commercial reagents were purchased from Sigma-Aldrich, VWR, Alfa Aesar, TCI America, Strem Chemicals Inc., or Frontier Scientific and were used without further purification unless otherwise noted. Solvents were purified via passage through packed columns as described by Pangborn and coworkers¹ (THF, Et₂O, CH₃CN, and CH₂Cl₂: dry neutral alumina; benzene and toluene: dry neutral alumina and Q5 reactant; DMF: activated molecular sieves). All water was deionized prior to use. Triethylamine and pyridine were freshly distilled under an atmosphere of nitrogen from CaH₂.

General Experimental Procedures. Unless noted, all reactions were performed in flame-dried round bottom or modified Schlenk flasks fitted with rubber septa under a positive pressure of argon or nitrogen. Organic solutions were concentrated via rotary evaporation under reduced pressure with a bath temperature of 35–40 °C. Reactions were monitored by analytical thin layer chromatography (TLC) performed using the indicated solvent. Compounds were visualized by exposure to a UV lamp ($\lambda = 254$ nm) and/or a solution of basic KMnO₄ followed by brief heating using a Varitemp heat gun. Column chromatography was performed using standard methods² or on a Teledyne-Isco CombiFlash Rf purification system using EM Science silica gel 60Å (230-400 mesh). For loading, compounds were adsorbed onto non acid-washed Celite under reduced pressure from an acetone solution. Specifically, for a 1 g mixture of crude material the sample is dissolved in reagent grade acetone (25 to 50 mL) and to the flask is added Celite 454 Filter Aid

(5 to 15 g). The mixture is then concentrated under reduced pressure to afford a powder, which is then loaded on top of a silica gel column. The procedure is typically repeated with a small amount of acetone (5 mL) and Celite (2 g) to ensure quantitative transfer. Cryocools are commercially available circulating cooling baths.

Structural analysis. ^1H , ^{13}C , and ^{19}F NMR spectra were recorded at 23 °C on a Inova-500 (500 MHz). Chemical shifts (δ) are reported in parts per million (ppm) downfield from tetramethylsilane and referenced to residual protium in the NMR solvent (CHCl_3 , $\delta = 7.26$) or to added tetramethylsilane ($\delta = 0.00$). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = sextet, sept = septet, m = multiplet, b = broad, app = apparent), coupling constant (J) in Hertz (Hz), and integration. ^{13}C NMR shifts (δ) are reported in ppm downfield from tetramethylsilane and referenced to carbon resonances in the NMR solvent (CDCl_3 , $\delta = 77.0$) or to added tetramethylsilane ($\delta = 0.00$). Carbons bearing boron substituents were not observed (quadrupolar relaxation). High resolution mass spectra (HRMS) were performed by Jennifer Wang at the Harvard University Mass Spectrometry Laboratory. Infrared spectra were collected from a thin film on a Bruker Optics Tensor 27 FTIR spectrometer. Absorption maxima (ν_{max}) are reported in wavenumbers (cm^{-1}). High-performance liquid chromatography (HPLC) analysis was performed using an Agilent 1200 series quaternary HPLC system with commercially available ChiralPak and ChiralCel columns. X-ray crystallographic analyses were carried out by Dr. Shao-Liang Zheng at the Harvard University X-Ray facility.

II. Synthesis of catalyst **2d**



Aryl iodide **2d.** To a 250 mL round bottom flask charged with a stir bar was added 2-iodoresorcinol³ (4.0 g, 17.0 mmol, 1.0 eq.), benzyl (*S*)-(-)-lactate (6.4 g, 35.7 mmol, 2.1 eq.), and triphenylphosphine (10.3 g, 39.0 mmol, 2.3 eq.). A septum was affixed and the flask was flushed with N_2 . THF (85 mL) was then added. The solution was cooled to 0 °C. Diisopropyl azodicarboxylate (DIAD, 7.7 mL, 39.0 mmol, 2.3 eq.) was added dropwise. The solution was warmed to 23 °C and stirred at this temperature for 20 h. After this time, basic alumina (8.0 g) was added to the reaction solution. The suspension was stirred at 23 °C for 10 min. The suspension was filtered and the filtrate was concentrated under reduced pressure. The resulting residue was dry loaded onto celite and purified by column chromatography through a plug of basic alumina followed directly by a column of silica gel (hexanes:Et₂O 100:0 → 80:20) to afford aryl iodide **2d** as a clear, colorless oil (8.6 g, 90% yield).

TLC (hexanes:EtOAc 6:1)

$R_f = 0.28$, stained by KMnO_4

^1H -NMR (500 MHz, CDCl_3)

δ 7.37-7.29 (m, 10H), 7.03 (t, J = 8.5 Hz, 1H), 6.34 (d, J = 8.5 Hz, 2H), 5.21 (app dd, J = 15.5, 12.5 Hz, 4H), 4.82 (q, J = 6.5 Hz, 2H), 1.73 (d, J = 6.5 Hz, 6H).

^{13}C -NMR (125 MHz, CDCl_3)

δ 171.4, 158.2, 135.3, 129.5, 128.5, 128.4, 128.2, 107.0, 80.7, 74.2, 66.9, 18.6.

HRMS (method)

Calculated for $\text{C}_{26}\text{H}_{25}\text{IO}_6$ ($\text{M}+\text{H}$) $^+$: 561.0769

Found: 561.0782


IR (thin film, cm^{-1})

3033, 2989, 2941, 1752, 1587, 1459, 1251, 1131, 1104, 749, 698

$[\alpha]_{\text{D}}^{23}$ -32.4 (c = 1.0, CHCl_3)

III. Table 1. Optimization of reaction conditions.


Entry 1:




To a 1.5 mL polyethylene Eppendorf tube charged with a Teflon PTFE coated stir bar was added mCPBA (77%, 26.9 mg, 0.12 mmol, 1.2 eq.). The reaction vial was cooled in a dry ice/acetone bath to <-60 °C. To the cooled vial was added aryl iodide catalyst **2a** (7.1 mg, 0.01 mmol, 10 mol%) as a solution in CH_2Cl_2 (0.15 mL) followed by pyr·9HF (70% HF, 0.065 mL, 2.5 mmol HF, 25 eq. HF). The alkene methyl (*E*)-2-(prop-1-en-1-yl)benzoate **1a** (17.6 mg, 0.10 mmol) was added as a solution in CH_2Cl_2 (0.10 mL, 0.40 M total concentration). The tube was capped and transferred to a -50 °C continuous cooling bath with vigorous stirring (vigorous stirring of the heterogeneous mixture is important to ensure reproducible conversion) at -50 °C for 24 h. After this time, the crude reaction suspension was quenched by being added to a cooled (-78 °C) suspension of basic alumina (0.5 g) in CH_2Cl_2 (2.0 mL). The resulting suspension was warmed to 23 °C and stirred at this temperature for 10 min. The suspension was filtered through a plug of basic alumina, eluting with CH_2Cl_2 . The crude reaction solution was analyzed by chiral GC.

87% *ee*, Chiral GC (β -Cyclosil, 60 °C to 180 °C, 10 psi); t_{R} (major) = 44.4 min, t_{R} (minor) = 44.7 min. 72% GC yield based on a dodecane internal standard.


Racemic sample:



Enriched sample:



Entry 2:




To a 1.5 mL polyethylene Eppendorf tube charged with a Teflon PTFE coated stir bar was added mCPBA (77%, 26.9 mg, 0.12 mmol, 1.2 eq.). The reaction vial was cooled in a dry ice/acetone bath to <-60 °C. To the cooled vial was added aryl iodide catalyst **2b** (5.6 mg, 0.01 mmol, 10

crude reaction suspension was quenched by being added to a cooled (-78 °C) suspension of basic alumina (0.5 g) in CH₂Cl₂ (2.0 mL). The resulting suspension was warmed to 23 °C and stirred at this temperature for 10 min. The suspension was filtered through a plug of basic alumina, eluting with CH₂Cl₂. The crude reaction solution was analyzed by chiral GC.

95% *ee*, Chiral GC (β-Cyclosil, 60 °C to 180 °C, 10 psi); *t_R*(major) = 44.4 min, *t_R*(minor) = 44.7 min. 86% GC yield based on a dodecane internal standard.

Enriched sample:



1.0 mmol reaction:

To a 7 mL low-density polyethylene vial with snap cap charged with a Teflon PTFE coated stir bar was added mCPBA (77%, 269 mg, 1.2 mmol, 1.2 eq.). The reaction vial was cooled in a dry ice/acetone bath to <-60 °C. To the cooled vial was added aryl iodide catalyst **2d** (56.0 mg, 0.10 mmol, 10 mol%) as a solution in CH₂Cl₂ (1.5 mL) followed by pyr•9HF (70% HF, 0.65 mL, 25 mmol HF, 25 eq. HF). The alkene (*E*)-2-(prop-1-en-1-yl)benzoate **1a** (1.0 mmol) was added as a solution in CH₂Cl₂ (1.0 mL, 0.40 M total concentration). The tube was capped and transferred to a -50 °C cryocool with vigorous stirring (vigorous stirring of the heterogeneous mixture is important to ensure reproducible conversion) at -50 °C for 24 h. After this time, the crude reaction suspension was quenched by being added to a cooled (-78 °C) suspension of basic alumina (2.5 g) in CH₂Cl₂ (5.0 mL). The resulting suspension was warmed to 23 °C and stirred at this temperature for 10 min. The suspension was filtered through a plug of basic alumina, eluting with CH₂Cl₂. The solution was concentrated under reduced pressure. The resulting residue was dry loaded onto celite and purified by column chromatography on silica gel (hexanes:EtOAc 100:0 → 80:20) to afford fluorolactone **3** as a white solid (122 mg, 68% yield).

TLC (hexanes:EtOAc 4:1)

R_f = 0.14, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 8.19 (d, $J = 7.5$ Hz, 1H), 7.69 (tt, $J = 7.5, 1.5$ Hz, 1H), 7.62 (tdd, $J = 7.5, 2.0, 1.5$ Hz, 1H), 7.52 (m, 1H), 5.32 (dd, $J = 49.5, 1.5$ Hz, 1H), 4.72 (dq, $J = 27.3, 6.8, 1.5$ Hz, 1H), 1.64 (d, $J = 6.5$ Hz, 3H).

^{13}C -NMR (125 MHz, CDCl_3)

δ 163.8, 134.6 (d, $J = 17.5$ Hz), 134.3 (d, $J = 3.0$ Hz), 131.3 (d, $J = 3.5$ Hz), 130.4 (d, $J = 3.0$ Hz), 128.8 (d, $J = 3.5$ Hz), 124.7 (d, $J = 2.5$ Hz), 85.3 (d, $J = 181.0$ Hz), 75.7 (d, $J = 22.5$ Hz), 16.1 (d, $J = 5.0$ Hz).

^{19}F -NMR (470 MHz, CDCl_3)

δ -183.0 (dd, $J = 49.5, 28.0$ Hz).

HRMS (ESI+)

Calculated for $\text{C}_{10}\text{H}_9\text{FO}_2$ ($\text{M}+\text{H}$) $^+$: 181.0659

Found: 181.0660

IR (thin film, cm^{-1})


2990, 2943, 1730, 1274, 1239, 1124, 1103, 901, 765, 723, 700, 649

$[\alpha]_{\text{D}}^{23} +78.8$ (c 1.0, CHCl_3)

95% *ee*, Chiral HPLC (CHIRALPAK OD-H, 5% isopropanol in hexanes, 1.0 mL/min, $\lambda = 230$ nm); t_{R} (major) = 17.4 min, t_{R} (minor) = 22.4 min.

Racemic sample:

DAD1 C, Sig=230,4 Ref=450,100 (AL\DEF_LC 2015-06-12 14-19-01\EMW-477A-IV-79-RAC.D)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.374	BB	0.4220	1.23833e4	440.47375	49.9442
2	22.120	BB	0.5113	1.24110e4	362.61212	50.0558

Totals : 2.47943e4 803.08588

Enriched sample:


DAD1 C, Sig=230,4 Ref=450,100 (AL\DEF_LC 2015-06-12 14-19-01\EMW-477A-IV-79-1MMOLD)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.353	BB	0.4142	1.18424e4	428.77740	97.7392
2	22.411	BB	0.4571	273.92612	8.99970	2.2608

Totals : 1.21164e4 437.77710


Entry 5:




To a 1.5 mL polyethylene Eppendorf tube charged with a Teflon PTFE coated stir bar was added mCPBA (77%, 26.9 mg, 0.12 mmol, 1.2 eq.). The reaction vial was cooled in a dry ice/acetone bath to <-60 °C. To the cooled vial was added aryl iodide catalyst **2d** (5.6 mg, 0.01 mmol, 10 mol%) as a solution in CH₂Cl₂ (0.15 mL) followed by pyr·9HF (70% HF, 0.065 mL, 2.5 mmol HF, 25 eq. HF). The alkene isopropyl (*E*)-2-(prop-1-en-1-yl)benzoate **1b** (20.4 mg, 0.10 mmol) was added as a solution in CH₂Cl₂ (0.10 mL, 0.40 M total concentration). The tube was capped and transferred to a -50 °C cryocool with vigorous stirring (vigorous stirring of the heterogeneous mixture is important to ensure reproducible conversion) at -50 °C for 24 h. After this time, the crude reaction suspension was quenched by being added to a cooled (-78 °C) suspension of basic alumina (0.5 g) in CH₂Cl₂ (2.0 mL). The resulting suspension was warmed to 23 °C and stirred at this temperature for 10 min. The suspension was filtered through a plug of basic alumina, eluting with CH₂Cl₂. The crude reaction solution was analyzed by chiral GC.

95% *ee*, Chiral GC (β-Cyclosil, 60 °C to 180 °C, 10 psi); *t_R*(major) = 44.4 min, *t_R*(minor) = 44.6 min. 72% GC yield based on a dodecane internal standard.

Enriched sample:




Entry 6:



To a 1.5 mL polyethylene Eppendorf tube charged with a Teflon PTFE coated stir bar was added mCPBA (77%, 26.9 mg, 0.12 mmol, 1.2 eq.). The reaction vial was cooled in a dry ice/acetone bath to <-60 °C. To the cooled vial was added aryl iodide catalyst **2d** (5.6 mg, 0.01 mmol, 10 mol%) as a solution in CH₂Cl₂ (0.15 mL) followed by pyr·9HF (70% HF, 0.065 mL, 2.5 mmol HF, 25 eq. HF). The alkene benzyl (*E*)-2-(prop-1-en-1-yl)benzoate **1c** (25.2 mg, 0.10 mmol) was added as a solution in CH₂Cl₂ (0.10 mL, 0.40 M total concentration). The tube was capped and transferred to a -50 °C cryocool with vigorous stirring (vigorous stirring of the heterogeneous mixture is important to ensure reproducible conversion) at -50 °C for 24 h. After this time, the crude reaction suspension was quenched by being added to a cooled (-78 °C) suspension of basic alumina (0.5 g) in CH₂Cl₂ (2.0 mL). The resulting suspension was warmed to 23 °C and stirred at this temperature for 10 min. The suspension was filtered through a plug of basic alumina, eluting with CH₂Cl₂. The crude reaction solution was analyzed by chiral GC.

87% *ee*, Chiral GC (β-Cyclosil, 60 °C to 180 °C, 10 psi); *t_R*(major) = 44.4 min, *t_R*(minor) = 44.7 min. 42% GC yield based on a dodecane internal standard.


Enriched sample:



Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	44.387	MM	0.1384	175.19818	21.09846	93.91276
2	44.651	MM	0.1402	11.35600	1.35027	6.08724

Totals : 186.55418 22.44873


Entry 7:



To a 1.5 mL polyethylene Eppendorf tube charged with a Teflon PTFE coated stir bar was added mCPBA (77%, 26.9 mg, 0.12 mmol, 1.2 eq.). The reaction vial was cooled in a dry ice/acetone bath to <-60 °C. To the cooled vial was added aryl iodide catalyst **2d** (5.6 mg, 0.01 mmol, 10 mol%) as a solution in CH₂Cl₂ (0.15 mL) followed by pyr•9HF (70% HF, 0.065 mL, 2.5 mmol HF, 25 eq. HF). The alkene (*E*)-2-(prop-1-en-1-yl)benzoic acid **1d** (16.2 mg, 0.10 mmol) was added as a solution in CH₂Cl₂ (0.10 mL, 0.40 M total concentration). The tube was capped and transferred to a -50 °C cryocool with vigorous stirring (vigorous stirring of the heterogeneous mixture is important to ensure reproducible conversion) at -50 °C for 24 h. After this time, the crude reaction suspension was quenched by being added to a cooled (-78 °C) suspension of basic alumina (0.5 g) in CH₂Cl₂ (2.0 mL). The resulting suspension was warmed to 23 °C and stirred at this temperature for 10 min. The suspension was filtered through a plug of basic alumina, eluting with CH₂Cl₂. The crude reaction solution was analyzed by chiral GC.


89% *ee*, Chiral GC (β-Cyclosil, 60 °C to 180 °C, 10 psi); *t_R*(major) = 44.5 min, *t_R*(minor) = 44.7 min. 95% GC yield based on a dodecane internal standard.

Enriched sample:



See page SI-77 for a 1 mmol scale reaction with isolated yield.


Footnote 15:




To a 1.5 mL polyethylene Eppendorf tube charged with a Teflon PTFE coated stir bar was added mCPBA (77%, 26.9 mg, 0.12 mmol, 1.2 eq.). The reaction vial was cooled in a dry ice/acetone bath to <-60 °C. To the cooled vial was added aryl iodide catalyst **2d** (5.6 mg, 0.01 mmol, 10 mol%) as a solution in CH₂Cl₂ (0.15 mL) followed by pyr·9HF (70% HF, 0.026 mL, 1.0 mmol HF, 10 eq. HF). The alkene methyl (*E*)-2-(prop-1-en-1-yl)benzoate **1a** (17.6 mg, 0.10 mmol) was added as a solution in CH₂Cl₂ (0.10 mL, 0.40 M total concentration). The tube was capped and transferred to a -50 °C cryocool with vigorous stirring (vigorous stirring of the heterogeneous mixture is important to ensure reproducible conversion) at -50 °C for 24 h. After this time, the crude reaction suspension was quenched by being added to a cooled (-78 °C) suspension of basic alumina (0.5 g) in CH₂Cl₂ (2.0 mL). The resulting suspension was warmed to 23 °C and stirred at this temperature for 10 min. The suspension was filtered through a plug of basic alumina, eluting with CH₂Cl₂. The crude reaction solution was analyzed by chiral GC.

93% *ee*, Chiral GC (β-Cyclosil, 60 °C to 180 °C, 10 psi); *t_R*(major) = 44.4 min, *t_R*(minor) = 44.7 min. 28% GC yield based on a dodecane internal standard.

Enriched sample:




Footnote 15:




To a 1.5 mL polyethylene Eppendorf tube charged with a Teflon PTFE coated stir bar was added mCPBA (77%, 26.9 mg, 0.12 mmol, 1.2 eq.). The reaction vial was cooled in a dry ice/acetone bath to <-60 °C. To the cooled vial was added aryl iodide catalyst **2d** (5.6 mg, 0.01 mmol, 10 mol%) as a solution in CH₂Cl₂ (0.15 mL) followed by pyr•9HF (70% HF, 0.13 mL, 5.0 mmol HF, 50 eq. HF). The alkene methyl (*E*)-2-(prop-1-en-1-yl)benzoate **1a** (17.6 mg, 0.10 mmol) was added as a solution in CH₂Cl₂ (0.10 mL, 0.40 M total concentration). The tube was capped and transferred to a -50 °C cryocool with vigorous stirring (vigorous stirring of the heterogeneous mixture is important to ensure reproducible conversion) at -50 °C for 24 h. After this time, the crude reaction suspension was quenched by being added to a cooled (-78 °C) suspension of basic alumina (0.5 g) in CH₂Cl₂ (2.0 mL). The resulting suspension was warmed to 23 °C and stirred at this temperature for 10 min. The suspension was filtered through a plug of basic alumina, eluting with CH₂Cl₂. The crude reaction solution was analyzed by chiral GC.

93% *ee*, Chiral GC (β-Cyclosil, 60 °C to 180 °C, 10 psi); t_R(major) = 44.4 min, t_R(minor) = 44.7 min. 83% GC yield based on a dodecane internal standard.

Enriched sample:



Footnote 15:




To a 1.5 mL polyethylene Eppendorf tube charged with a Teflon PTFE coated stir bar was added mCPBA (77%, 26.9 mg, 0.12 mmol, 1.2 eq.). The reaction vial was cooled in a dry ice/acetone bath to <-60 °C. To the cooled vial was added aryl iodide catalyst **2d** (5.6 mg, 0.01 mmol, 10 mol%) as a solution in CH₂Cl₂ (0.15 mL) followed by pyr·9HF (70% HF, 0.065 mL, 2.5 mmol HF, 25 eq. HF). The alkene methyl (*E*)-2-(prop-1-en-1-yl)benzoate **1a** (17.6 mg, 0.10 mmol) was added as a solution in CH₂Cl₂ (0.10 mL, 0.40 M total concentration). The tube was capped and transferred to a -20 °C cryocool with vigorous stirring (vigorous stirring of the heterogeneous mixture is important to ensure reproducible conversion) at -20 °C for 24 h. After this time, the crude reaction suspension was quenched by being added to a cooled (-78 °C) suspension of basic alumina (0.5 g) in CH₂Cl₂ (2.0 mL). The resulting suspension was warmed to 23 °C and stirred at this temperature for 10 min. The suspension was filtered through a plug of basic alumina, eluting with CH₂Cl₂. The crude reaction solution was analyzed by chiral GC.

86% *ee*, Chiral GC (β-Cyclosil, 60 °C to 180 °C, 10 psi); *t*_R(major) = 44.4 min, *t*_R(minor) = 44.7 min. 71% GC yield based on a dodecane internal standard.

Enriched sample:

K_3PO_4 (9.0 mL, 5 eq.) at 45 °C for 21 h. Brine (40 mL) and Et_2O (40 mL) were used in the workup. Alkene **1a** was isolated as a pale yellow oil (434 mg, 46% yield). Characterization of this compound was consistent with previously reported data.⁴



methyl (*E*)-2-methyl-6-(prop-1-en-1-yl)benzoate 4a. Following the “general procedure for the synthesis of substrates 4a-o”, methyl 2-bromo-6-methylbenzoate **SI-1e** (573 mg, 2.5 mmol, 1.0 eq.), *trans*-1-propenylboronic acid pinacol ester **SI-2** (462 mg, 2.8 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (98 mg, 0.13 mmol, 5 mol%) were reacted in THF (6.2 mL, 0.4 M) and 3 M aqueous K_3PO_4 (4.0 mL, 5 eq.) at 45 °C for 19 h. Brine (40 mL) and Et_2O (40 mL) were used in the workup. Alkene **4a** was isolated as a pale yellow oil (474 mg, 99% yield).

TLC (hexanes:EtOAc 9:1)

$R_f = 0.49$, stained by $KMnO_4$

1H -NMR (500 MHz, $CDCl_3$)

δ 7.35 (d, $J = 7.5$ Hz, 1H), 7.25 (t, $J = 7.0$ Hz, 1H), 7.07 (d, $J = 7.5$ Hz, 1H), 6.41 (d, $J = 16.0$ Hz, 1H), 6.21 (dq, $J = 16.0, 7.0$ Hz, 1H), 3.94 (s, 3H), 2.32 (s, 3H), 1.89 (d, $J = 7.0$ Hz, 3H).

^{13}C -NMR (125 MHz, $CDCl_3$)

δ 170.4, 135.4, 134.8, 132.2, 129.3, 128.7, 128.4, 127.9, 123.0, 52.0, 19.6, 18.8.


HRMS (ESI+)

Calculated for $C_{12}H_{14}O_2$ ($M+H$)⁺: 191.1067

Found: 191.1072

IR (thin film, cm^{-1})

3028, 2950, 1724, 1435, 1265, 1233, 1114, 1069, 958, 767



methyl (*E*)-5-methyl-2-(prop-1-en-1-yl)benzoate 4b. Following the “general procedure for the synthesis of substrates 4a-o”, methyl 2-iodo-5-methylbenzoate **SI-1f** (690 mg, 2.5 mmol, 1.0 eq.), *trans*-1-propenylboronic acid pinacol ester **SI-2** (462 mg, 2.8 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (98 mg, 0.13 mmol, 5 mol%) were reacted in THF (6.2 mL, 0.4 M) and 3 M aqueous K₃PO₄ (4.0 mL, 5 eq.) at 45 °C for 22 h. Brine (40 mL) and Et₂O (40 mL) were used in the workup. Alkene **4b** was isolated as a pale yellow oil (475 mg, 99% yield).

TLC (hexanes:EtOAc 9:1)

R_f = 0.49, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 7.66 (s, 1H), 7.44 (d, *J* = 8.5 Hz, 1H), 7.25 (d, *J* = 7.5 Hz, 1H), 7.13 (app d, *J* = 16.0 Hz, 1H), 6.13 (dq, *J* = 15.5, 6.5 Hz, 1H), 3.91 (s, 3H), 2.36 (s, 3H), 1.93 (dd, *J* = 6.5, 1.5 Hz, 3H).

¹³C-NMR (125 MHz, CDCl₃)

δ 168.2, 136.8, 136.2, 132.8, 130.6, 129.4, 127.9, 127.7, 127.1, 52.0, 20.9, 18.8.


HRMS (ESI+)

Calculated for C₁₂H₁₄O₂ (M+H)⁺: 191.1067

Found: 191.1075

IR (thin film, cm⁻¹)

2950, 2915, 2853, 1719, 1433, 1290, 1249, 1198, 1143, 1097, 1074, 965, 838, 776



methyl (*E*)-4-methyl-2-(prop-1-en-1-yl)benzoate 4c. Following the “general procedure for the synthesis of substrates 4a-o”, methyl 2-bromo-4-methylbenzoate **SI-1g** (573 mg, 2.5 mmol, 1.0 eq.), *trans*-1-propenylboronic acid pinacol ester **SI-2** (462 mg, 2.8 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (98 mg, 0.13 mmol, 5 mol%) were reacted in THF (6.2 mL, 0.4 M) and 3 M aqueous K₃PO₄ (4.0 mL, 5 eq.) at 45 °C for 22 h. Brine (40 mL) and Et₂O (40 mL) were used in the workup. Alkene **4c** was isolated as a pale yellow oil (475 mg, 99% yield).

TLC (hexanes:EtOAc 9:1)

R_f = 0.49, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 7.78 (d, *J* = 7.5 Hz, 1H), 7.34 (s, 1H), 7.20 (dq, *J* = 16.0, 1.5 Hz, 1H), 7.07 (d, *J* = 8.0 Hz, 1H), 6.15 (dq, *J* = 16.0, 7.0 Hz, 1H), 3.89 (s, 3H), 2.39 (s, 3H), 1.94 (dd, *J* = 6.5, 1.5 Hz, 3H).

^{13}C -NMR (125 MHz, CDCl_3)

δ 168.0, 142.4, 139.9, 130.5, 129.9, 128.3, 127.9, 127.3, 125.1, 51.8, 21.5, 18.8.


HRMS (ESI+)

Calculated for $\text{C}_{12}\text{H}_{14}\text{O}_2$ ($\text{M}+\text{H}$) $^+$: 191.1067

Found: 191.1074

IR (thin film, cm^{-1})

2950, 2913, 2852, 1716, 1607, 1433, 1284, 1243, 1189, 1138, 1098, 1076, 961, 816, 767



methyl (*E*)-3-methyl-2-(prop-1-en-1-yl)benzoate 4d. Following the “general procedure for the synthesis of substrates 4a-o”, methyl 2-bromo-3-methylbenzoate **SI-1h** (573 mg, 2.5 mmol, 1.0 eq.), *trans*-1-propenylboronic acid pinacol ester **SI-2** (462 mg, 2.8 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (98 mg, 0.13 mmol, 5 mol%) were reacted in THF (6.2 mL, 0.4 M) and 3 M aqueous K_3PO_4 (4.0 mL, 5 eq.) at 45 °C for 16.5 h. Brine (40 mL) and Et_2O (40 mL) were used in the workup. Alkene **4d** was isolated as a pale yellow solid (443 mg, 93% yield).

TLC (hexanes:EtOAc 6:1)

R_f = 0.46, stained by KMnO_4

^1H -NMR (500 MHz, CDCl_3)

δ 7.52 (d, J = 8.0 Hz, 1H), 7.30 (d, J = 7.5 Hz, 1H), 7.17 (t, J = 7.5 Hz, 1H), 6.63 (d, J = 16.0 Hz, 1H), 5.64 (dq, J = 16.0, 6.5 Hz, 1H), 3.85 (s, 3H), 2.34 (s, 3H), 1.90 (dd, J = 6.5, 1.5 Hz, 3H).

^{13}C -NMR (125 MHz, CDCl_3)

δ 169.8, 138.1, 136.9, 132.9, 131.3, 130.2, 128.3, 126.8, 126.1, 52.0, 20.7, 18.8.


HRMS (ESI+)

Calculated for $\text{C}_{12}\text{H}_{14}\text{O}_2$ ($\text{M}+\text{H}$) $^+$: 191.1067

Found: 191.1073

IR (thin film, cm^{-1})

3019, 2949, 2916, 1720, 1434, 1283, 1262, 1208, 1190, 1172, 1132, 1092, 1013, 964, 939, 782, 746



methyl (*E*)-2-(prop-1-en-1-yl)-5-(trifluoromethoxy)benzoate 4e. Following the “general procedure for the synthesis of substrates 4a-o”, methyl 2-bromo-5-(trifluoromethoxy)benzoate **SI-1i** (748 mg, 2.5 mmol, 1.0 eq.), *trans*-1-propenylboronic acid **SI-3** (300 mg, 3.5 mmol, 1.4 eq.), and 2nd generation XPhosPd cycle (98 mg, 0.13 mmol, 5 mol%) were reacted in THF (6.2 mL, 0.4 M) and 3 M aqueous K₃PO₄ (4.0 mL, 5 eq.) at 45 °C for 19 h. Brine (40 mL) and Et₂O (40 mL) were used in the workup. Alkene **4e** was isolated as a pale yellow oil (545 mg, 84% yield).

TLC (hexanes:EtOAc 4:1)

R_f = 0.30, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 7.72 (s, 1H), 7.55 (d, *J* = 8.5 Hz, 1H), 7.31 (d, *J* = 7.5 Hz, 1H), 7.15 (d, *J* = 15.5 Hz, 1H), 6.16 (ddq, 15.5, 7.0, 1.5 Hz, 1H), 3.93 (s, 3H), 1.94 (dt, *J* = 6.5, 2.0 Hz, 3H).

¹³C-NMR (125 MHz, CDCl₃)

δ 166.6, 147.4, 138.6, 129.9, 129.1, 128.8, 128.5, 124.5, 122.7, 120.4 (d, *J* = 258 Hz), 52.3 (d, *J* = 3.5 Hz), 18.8.

¹⁹F-NMR (470 MHz, CDCl₃)

δ -58.0.


HRMS (ESI+)

Calculated for C₁₂H₁₁F₃O₃ (M+H)⁺: 261.0733

Found: 261.0726

IR (thin film, cm⁻¹)

2955, 2918, 2855, 1726, 1491, 1437, 1247, 1204, 1157, 1099, 1071, 991, 964, 944, 845, 776



methyl (*E*)-5-bromo-2-(prop-1-en-1-yl)benzoate 4f. Following the “general procedure for the synthesis of substrates 4a-o”, methyl 5-bromo-2-iodobenzoate **SI-1j** (852 mg, 2.5 mmol, 1.0 eq.),

trans-1-propenylboronic acid pinacol ester **SI-2** (420 mg, 2.5 mmol, 1.0 eq.), and 2nd generation XPhosPd cycle (39 mg, 0.05 mmol, 2 mol%) were reacted in THF (6.2 mL, 0.4 M) and 3 M aqueous K₃PO₄ (4.0 mL, 5 eq.) at 23 °C for 22 h. Brine (40 mL) and Et₂O (40 mL) were used in the workup. Alkene **4f** was isolated as a pale yellow oil (408 mg, 64% yield, 85% purity).

TLC (hexanes:EtOAc 6:1)

R_f = 0.55, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 7.99 (d, *J* = 2.0 Hz, 1H), 7.55 (dd, *J* = 8.5, 2.5 Hz, 1H), 7.40 (d, *J* = 9.0 Hz, 1H), 7.11 (dd, *J* = 16.0, 1.5 Hz, 1H), 6.17 (dq, *J* = 16.0, 6.5 Hz, 1H), 3.92 (s, 3H), 1.93 (dd, *J* = 7.0, 2.0 Hz, 3H).

¹³C-NMR (125 MHz, CDCl₃)

δ 166.7, 142.6, 138.6, 134.8, 133.1, 129.5, 128.7, 128.6, 120.0, 52.3, 18.8.


HRMS (ESI+)

Calculated for C₁₁H₁₁BrO₂ (M+H)⁺: 255.0015

Found: 255.0008

IR (thin film, cm⁻¹)

3010, 2949, 2912, 2875, 2850, 1720, 1475, 1434, 1282, 1235, 1204, 1143, 1103, 1074, 964, 839, 774



methyl (*E*)-5-chloro-2-(prop-1-en-1-yl)benzoate 4g. Following the “general procedure for the synthesis of substrates 4a-o”, methyl 2-bromo-5-chlorobenzoate **SI-1k** (624 mg, 2.5 mmol, 1.0 eq.), *trans*-1-propenylboronic acid pinacol ester **SI-2** (420 mg, 2.8 mmol, 1.0 eq.), and 2nd generation XPhosPd cycle (98 mg, 0.13 mmol, 5 mol%) were reacted in THF (6.2 mL, 0.4 M) and 3 M aqueous K₃PO₄ (4.0 mL, 5 eq.) at 23 °C for 16.5 h. Brine (40 mL) and Et₂O (40 mL) were used in the workup. Alkene **4g** was isolated as a pale yellow solid (508 mg, 96% yield).

TLC (hexanes:EtOAc 6:1)

R_f = 0.59, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 7.84 (d, *J* = 2.5 Hz, 1H), 7.47 (d, *J* = 8.5 Hz, 1H), 7.40 (dd, *J* = 8.5, 2.0 Hz, 1H), 7.12 (dd, *J* = 16.0, 2.0 Hz, 1H), 6.16 (dq, *J* = 15.5, 6.5 Hz, 1H), 3.91 (s, 3H), 1.93 (dd, *J* = 6.5, 1.5 Hz, 3H).

^{13}C -NMR (125 MHz, CDCl_3)

δ 166.8, 138.2, 132.2, 132.0, 130.1, 129.4, 129.1, 128.6, 128.5, 52.3, 18.8.


HRMS (ESI+)

Calculated for $\text{C}_{11}\text{H}_{11}\text{ClO}_2$ (M+H) $^+$: 211.0520

Found: 211.0515

IR (thin film, cm^{-1})

3011, 2913, 2878, 1721, 1476, 1434, 1284, 1232, 1204, 1142, 1112, 1098, 1073, 964, 840, 774, 727



methyl (*E*)-2-fluoro-6-(prop-1-en-1-yl)benzoate **4h.** Following the “general procedure for the synthesis of substrates 4a-o”, methyl 2-bromo-6-fluorobenzoate **SI-11** (583 mg, 2.5 mmol, 1.0 eq.), *trans*-1-propenylboronic acid pinacol ester **SI-2** (462 mg, 2.8 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (98 mg, 0.13 mmol, 5 mol%) were reacted in THF (6.2 mL, 0.4 M) and 3 M aqueous K_3PO_4 (4.0 mL, 5 eq.) at 45 °C for 23 h. Brine (40 mL) and Et_2O (40 mL) were used in the workup. Alkene **4h** was isolated as a pale yellow oil (367 mg, 76% yield).

TLC (hexanes:EtOAc 6:1)

R_f = 0.62, stained by KMnO_4

^1H -NMR (500 MHz, CDCl_3)

δ 7.36-7.26 (m, 2H), 6.99-6.94 (m, 1H), 6.52 (dd, J = 15.5, 1.5 Hz, 1H), 6.26 (dq, J = 15.5, 6.5 Hz, 1H), 3.96 (s, 3H), 1.90 (dd, J = 6.5, 1.5 Hz, 3H).

^{13}C -NMR (125 MHz, CDCl_3)

δ 166.2, 159.9 (d, J = 250.0 Hz), 138.6, 131.2 (d, J = 9.0 Hz), 130.3, 127.0 (d, J = 2.5 Hz), 121.3 (d, J = 3.0 Hz), 119.8 (d, J = 16.0 Hz), 113.7 (d, J = 22.0 Hz), 52.6, 18.8.

^{19}F -NMR (470 MHz, CDCl_3)

δ -115.1 (dd, J = 9.5, 5.5 Hz).


HRMS (ESI+)

Calculated for $\text{C}_{11}\text{H}_{11}\text{FO}_2$ (M+H) $^+$: 195.0816

Found: 195.0815

IR (thin film, cm^{-1})

3037, 2953, 2916, 1729, 1611, 1568, 1467, 1431, 1284, 1269, 1240, 1106, 1059, 958, 918, 830, 773, 764, 536



methyl (*E*)-5-fluoro-2-(prop-1-en-1-yl)benzoate 4i. Following the “general procedure for the synthesis of substrates 4a-o”, methyl 2-bromo-5-fluorobenzoate **SI-1m** (583 mg, 2.5 mmol, 1.0 eq.), *trans*-1-propenylboronic acid pinacol ester **SI-2** (462 mg, 2.8 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (98 mg, 0.13 mmol, 5 mol%) were reacted in THF (6.2 mL, 0.4 M) and 3 M aqueous K₃PO₄ (4.0 mL, 5 eq.) at 45 °C for 22 h. Brine (40 mL) and Et₂O (40 mL) were used in the workup. Alkene **4i** was isolated as a pale yellow oil (480 mg, 99% yield).

TLC (hexanes:EtOAc 9:1)

R_f = 0.49, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 7.53 (dd, *J* = 9.5, 3.0 Hz, 1H), 7.47 (dd, *J* = 8.5, 5.5 Hz, 1H), 7.17-7.06 (m, 2H), 6.07 (dq, *J* = 15.5, 6.5 Hz, 1H), 3.89 (s, 3H), 1.90 (dd, *J* = 7.0, 2.0 Hz, 3H).

¹³C-NMR (125 MHz, CDCl₃)

δ 166.8 (d, *J* = 2.5 Hz), 161.0 (d, *J* = 249.5 Hz), 136.0 (d, *J* = 4.0 Hz), 129.2 (d, *J* = 8.0 Hz), 129.0 (d, *J* = 7.0 Hz), 128.7, 128.6 (d, *J* = 1.5 Hz), 119.2 (d, *J* = 22.0 Hz), 116.8 (d, *J* = 23.0 Hz), 52.2, 18.7.

¹⁹F-NMR (470 MHz, CDCl₃)

δ -115.6 (m).


HRMS (ESI+)

Calculated for C₁₁H₁₁FO₂ (M+H)⁺: 195.0816

Found: 195.0812

IR (thin film, cm⁻¹)

3011, 2953, 2915, 2853, 1723, 1488, 1435, 1290, 1271, 1249, 1207, 1183, 1097, 1064, 982, 964, 887, 841, 775



methyl (*E*)-4-fluoro-2-(prop-1-en-1-yl)benzoate 4j. Following the “general procedure for the synthesis of substrates 4a-o”, methyl 2-bromo-4-fluorobenzoate **SI-1n** (583 mg, 2.5 mmol, 1.0 eq.), *trans*-1-propenylboronic acid pinacol ester **SI-2** (462 mg, 2.8 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (98 mg, 0.13 mmol, 5 mol%) were reacted in THF (6.2 mL, 0.4 M)

and 3 M aqueous K_3PO_4 (4.0 mL, 5 eq.) at 23 °C for 16.5 h. Brine (40 mL) and Et_2O (40 mL) were used in the workup. Alkene **4j** was isolated as a pale yellow solid (440 mg, 91% yield).

TLC (hexanes:EtOAc 6:1)

R_f = 0.55, stained by $KMnO_4$

1H -NMR (500 MHz, $CDCl_3$)

δ 7.88 (dd, J = 8.5, 6.0 Hz, 1H), 7.23-7.16 (m, 2H), 6.95-6.89 (m, 1H), 6.16 (dq, J = 16.0, 6.5 Hz, 1H), 3.88 (s, 3H), 1.92 (dd, J = 6.5, 1.5 Hz, 3H).

^{13}C -NMR (125 MHz, $CDCl_3$)

δ 167.0, 164.8 (d, J = 253.0 Hz), 143.0 (d, J = 8.5 Hz), 133.0 (d, J = 9.5 Hz), 129.9, 128.9 (d, J = 2.5 Hz), 123.9 (d, J = 2.0 Hz), 113.7 (d, J = 19.0 Hz), 113.5 (d, J = 18.5 Hz), 52.0, 18.7.

^{19}F -NMR (470 MHz, $CDCl_3$)

δ -107.6.


HRMS (ESI+)

Calculated for $C_{11}H_{11}FO_2$ (M+H) $^+$: 195.0816

Found: 195.0819

IR (thin film, cm^{-1})

3012, 2953, 2914, 2854, 1719, 1606, 1577, 1434, 1279, 1242, 1219, 1189, 1163, 1115, 1099, 1075, 960, 874, 771



methyl (*E*)-3-fluoro-2-(prop-1-en-1-yl)benzoate 4k. Following the “general procedure for the synthesis of substrates 4a-o”, methyl 2-bromo-3-fluorobenzoate **SI-10** (583 mg, 2.5 mmol, 1.0 eq.), *trans*-1-propenylboronic acid pinacol ester **SI-2** (462 mg, 2.8 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (98 mg, 0.13 mmol, 5 mol%) were reacted in THF (6.2 mL, 0.4 M) and 3 M aqueous K_3PO_4 (4.0 mL, 5 eq.) at 45 °C for 19 h. Brine (40 mL) and Et_2O (40 mL) were used in the workup. Alkene **4k** was isolated as a pale yellow oil (465 mg, 96% yield).

TLC (hexanes:EtOAc 9:1)

R_f = 0.49, stained by $KMnO_4$

1H -NMR (500 MHz, $CDCl_3$)

δ 7.57-7.51 (m, 1H), 7.23-7.14 (m, 2H), 6.68 (d, J = 16.0 Hz, 1H), 6.25 (ddq, J = 15.5, 7.0, 2.0 Hz, 1H), 3.89 (s, 3H), 1.93 (d, J = 7.0 Hz, 3H).

^{13}C -NMR (125 MHz, CDCl_3)

δ 167.7 (d, $J = 4.0$ Hz), 160.6 (d, $J = 247.5$ Hz), 133.6 (d, $J = 10.0$ Hz), 131.4 (d, $J = 4.0$ Hz), 127.0 (d, $J = 9.5$ Hz), 126.7 (d, $J = 14.5$ Hz), 125.6 (d, $J = 4.0$ Hz), 122.2, 119.1 (d, $J = 24.0$ Hz), 52.2, 19.5.

^{19}F -NMR (470 MHz, CDCl_3)

δ -114.2 (t, $J = 8.0$ Hz).


HRMS (ESI+)

Calculated for $\text{C}_{11}\text{H}_{11}\text{FO}_2$ ($\text{M}+\text{H}$) $^+$: 195.0816

Found: 195.0821

IR (thin film, cm^{-1})

2953, 2915, 2853, 1721, 1454, 1433, 1287, 1257, 1194, 1174, 1140, 1099, 1001, 965, 900, 773, 753



methyl (*E*)-2-(prop-1-en-1-yl)-5-(trifluoromethyl)benzoate 4I. Following the “general procedure for the synthesis of substrates 4a-o”, methyl 2-bromo-5-(trifluoromethyl)benzoate **SI-1p** (708 mg, 2.5 mmol, 1.0 eq.), *trans*-1-propenylboronic acid pinacol ester **SI-2** (462 mg, 2.8 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (98 mg, 0.13 mmol, 5 mol%) were reacted in THF (6.2 mL, 0.4 M) and 3 M aqueous K_3PO_4 (4.0 mL, 5 eq.) at 45 °C for 23 h. Brine (40 mL) and Et_2O (40 mL) were used in the workup. Alkene **4I** was isolated as a pale yellow oil (526 mg, 86% yield).

TLC (hexanes:EtOAc 6:1)

$R_f = 0.68$, stained by KMnO_4

^1H -NMR (500 MHz, CDCl_3)

δ 8.11 (s, 1H), 7.68-7.61 (m, 2H), 7.20 (d, $J = 16.0$ Hz, 1H), 6.26 (dq, $J = 16.0, 6.5$ Hz, 1H), 3.93 (s, 3H), 1.95 (dd, $J = 7.0, 1.5$ Hz, 3H).

^{13}C -NMR (125 MHz, CDCl_3)

δ 166.7, 143.1, 131.4, 128.6, 128.2, 127.9 (dq, $J = 102.0, 3.5$ Hz) 127.6, 124.8, 122.7, 110.0, 52.3, 18.9.

^{19}F -NMR (470 MHz, CDCl_3)

δ -62.7.


HRMS (ESI+)

Calculated for $\text{C}_{12}\text{H}_{11}\text{F}_3\text{O}_2$ ($\text{M}+\text{H}$) $^+$: 245.0784

Found: 245.0778

IR (thin film, cm^{-1})

2955, 2917, 1725, 1336, 1273, 1236, 1211, 1168, 1120, 1101, 1084, 1075, 961, 848, 777, 691



methyl (E)-2-(prop-1-en-1-yl)-4-(trifluoromethyl)benzoate 4m. Following the “general procedure for the synthesis of substrates 4a-o”, methyl 2-bromo-4-(trifluoromethyl)benzoate **SI-1q** (708 mg, 2.5 mmol, 1.0 eq.), *trans*-1-propenylboronic acid pinacol ester **SI-2** (462 mg, 2.8 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (98 mg, 0.13 mmol, 5 mol%) were reacted in THF (6.2 mL, 0.4 M) and 3 M aqueous K_3PO_4 (4.0 mL, 5 eq.) at 45 °C for 19 h. Brine (40 mL) and Et_2O (40 mL) were used in the workup. Alkene **4m** was isolated as a pale yellow oil (573 mg, 94% yield).

TLC (hexanes:EtOAc 9:1)

R_f = 0.57, stained by KMnO_4

$^1\text{H-NMR}$ (500 MHz, CDCl_3)

δ 7.93 (d, J = 8.0 Hz, 1H), 7.78 (s, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.15 (dq, J = 15.5, 2.0 Hz, 1H), 6.26 (dq, J = 15.5, 6.5 Hz, 1H), 3.94 (s, 3H), 1.96 (dd, J = 7.0, 2.0 Hz, 3H).

$^{13}\text{C-NMR}$ (125 MHz, CDCl_3)

δ 167.0, 140.2, 133.5 (q, J = 32.0 Hz), 131.0, 130.8, 130.7, 128.4, 124.7, 123.4 (dq, J = 133.0, 4.5 Hz), 122.5, 52.4 (d, J = 2.0 Hz), 18.8.

$^{19}\text{F-NMR}$ (470 MHz, CDCl_3)

δ -63.3.


HRMS (ESI+)

Calculated for $\text{C}_{12}\text{H}_{11}\text{F}_3\text{O}_2$ ($\text{M}+\text{H}$)⁺: 245.0784

Found: 245.0788

IR (thin film, cm^{-1})

2955, 2917, 2856, 1725, 1335, 1312, 1289, 1276, 1245, 1167, 1124, 1089, 961, 894, 846, 776, 754, 707



dimethyl (*E*)-4-(prop-1-en-1-yl)isophthalate 4n. Following the “general procedure for the synthesis of substrates 4a-o”, dimethyl 4-bromoisophthalate **SI-1r** (683 mg, 2.5 mmol, 1.0 eq.), *trans*-1-propenylboronic acid pinacol ester **SI-2** (462 mg, 2.8 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (98 mg, 0.13 mmol, 5 mol%) were reacted in THF (6.2 mL, 0.4 M) and 3 M aqueous K₃PO₄ (4.0 mL, 5 eq.) at 45 °C for 23 h. Brine (40 mL) and Et₂O (40 mL) were used in the workup. Alkene **4n** was isolated as a pale yellow solid (437 mg, 75% yield).

TLC (hexanes:EtOAc 6:1)

R_f = 0.49, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 8.50 (d, *J* = 1.5 Hz, 1H), 8.06 (dd, *J* = 8.0, 2.0 Hz, 1H), 7.60 (d, *J* = 8.0 Hz, 1H), 7.21 (dd, *J* = 16.0, 2.0 Hz, 1H), 6.30 (dq, *J* = 15.5, 6.5 Hz, 1H), 3.92 (s, 6H), 1.95 (dd, *J* = 6.5, 1.5 Hz, 3H).

¹³C-NMR (125 MHz, CDCl₃)

δ 167.2, 166.2, 143.9, 132.5, 131.8, 131.4, 128.9, 128.1, 128.0, 127.1, 52.2, 19.0.


HRMS (ESI+)

Calculated for C₁₃H₁₄O₄ (M+H)⁺: 235.0965

Found: 235.0972

IR (thin film, cm⁻¹)

3001, 2952, 2913, 1716, 1607, 1433, 1305, 1262, 1226, 1142, 1116, 1099, 1073, 990, 962, 754



dimethyl (*E*)-2-(prop-1-en-1-yl)terephthalate 4o. Following the “general procedure for the synthesis of substrates 4a-o”, dimethyl 2-bromoterephthalate **SI-1s** (683 mg, 2.5 mmol, 1.0 eq.), *trans*-1-propenylboronic acid pinacol ester **SI-2** (462 mg, 2.8 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (98 mg, 0.13 mmol, 5 mol%) were reacted in THF (6.2 mL, 0.4 M) and 3 M aqueous K₃PO₄ (4.0 mL, 5 eq.) at 45 °C for 16.5 h. Brine (40 mL) and Et₂O (40 mL) were used in the workup. Alkene **4o** was isolated as a white solid (586 mg, 99% yield).

TLC (hexanes:EtOAc 6:1)

$R_f = 0.39$, stained by KMnO_4

$^1\text{H-NMR}$ (500 MHz, CDCl_3)

δ 8.14 (s, 1H), 7.84-7.79 (m, 2H), 7.07 (d, $J = 16.5$ Hz, 1H), 6.23 (dq, $J = 16.0, 6.5$ Hz, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 1.89 (dd, $J = 7.0, 1.5$ Hz, 3H).

$^{13}\text{C-NMR}$ (125 MHz, CDCl_3)

δ 167.3, 166.2, 139.6, 132.8, 131.6, 130.2, 130.0, 128.6, 128.2, 127.0, 52.3, 52.2, 18.8.


HRMS (ESI+)

Calculated for $\text{C}_{13}\text{H}_{14}\text{O}_4$ ($\text{M}+\text{H}$) $^+$: 235.0965


Found: 235.0971

IR (thin film, cm^{-1})


3002, 2952, 2914, 2852, 1717, 1433, 1287, 1237, 1200, 1110, 1073, 962, 747, 730



Methyl 2-vinylbenzoate 6a. Following the “general procedure for the synthesis of substrates 6a-h”, methyl 2-bromobenzoate **SI-1a** (968 mg, 4.5 mmol, 1.0 eq.), vinylboronic acid MIDA ester **SI-4** (906 mg, 5.0 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (177 mg, 0.23 mmol, 5 mol%) were reacted in THF (11.0 mL, 0.4 M) and 3 M aqueous K_3PO_4 (11.0 mL, 7.5 eq.) at 45 °C for 18 h. Brine (40 mL) and Et_2O (40 mL) were used in the workup. Alkene **6a** was isolated as a pale yellow oil (569 mg, 78% yield). Characterization of this compound was consistent with previously reported data.⁵



Methyl (*E*)-2-(pent-1-en-1-yl)benzoate 6b. Following the “general procedure for the synthesis of substrates 6a-h”, methyl 2-bromobenzoate **SI-1a** (857 mg, 4.0 mmol, 1.0 eq.), 1-penten-1-ylboronic acid **SI-5** (500 mg, 4.4 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (157 mg, 0.20 mmol, 5 mol%) were reacted in THF (10 mL, 0.4 M) and 3 M aqueous K_3PO_4 (6.6 mL, 5 eq.) at 45 °C for 18 h. Brine (40 mL) and Et_2O (40 mL) were used in the workup. Alkene **6b** was isolated as a pale yellow oil (780 mg, 96% yield). Characterization of this compound was consistent with previously reported data.⁶



Methyl (*E*)-2-(5-chloropent-1-en-1-yl)benzoate 6c. Following the “general procedure for the synthesis of substrates 6a-h”, methyl 2-bromobenzoate **SI-1a** (645 mg, 3.0 mmol, 1.0 eq.), *trans*-5-chloro-1-penten-1-ylboronic acid pinacol ester **SI-6** (760 mg, 3.3 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (118 mg, 0.15 mmol, 5 mol%) were reacted in THF (10.0 mL, 0.3 M) and 3 M aqueous K₃PO₄ (5.0 mL, 5 eq.) at 45 °C for 17 h. Brine (40 mL) and Et₂O (40 mL) were used in the workup. Alkene **6c** was isolated as a pale yellow oil (659 mg, 92% yield).

TLC (hexanes:EtOAc 9:1)

R_f = 0.50, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 7.87 (d, *J* = 8.0 Hz, 1H), 7.53 (d, *J* = 8.0 Hz, 1H), 7.46 (t, *J* = 7.5 Hz, 1H), 7.28 (t, *J* = 7.5 Hz, 1H), 7.20 (d, *J* = 16.0 Hz, 1H), 6.13-6.05 (m, 1H), 3.91 (s, 3H), 3.62 (t, *J* = 7.0 Hz, 2H), 2.43 (q, *J* = 7.0 Hz, 2H), 1.99 (p, *J* = 7.0 Hz, 2H).

¹³C-NMR (125 MHz, CDCl₃)

δ 167.9, 139.3, 132.0, 131.5, 130.3, 130.0, 128.2, 127.3, 126.8, 52.0, 44.3, 32.0, 30.2.


HRMS (ESI+)

Calculated for C₁₃H₁₅ClO₂ (M+H)⁺: 239.0833

Found: 239.0841

IR (thin film, cm⁻¹)

3063, 2997, 2951, 2846, 1719, 1481, 1434, 1249, 1159, 1075, 966, 745



Methyl (*E*)-2-(2-cyclohexylvinyl)benzoate 6d. Following the “general procedure for the synthesis of substrates 6a-h”, methyl 2-bromobenzoate **SI-1a** (517 mg, 2.4 mmol, 1.0 eq.), (*E*)-(2-cyclohexylvinyl)boronic acid **SI-7** (407 mg, 2.6 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (95 mg, 0.12 mmol, 5 mol%) were reacted in THF (6.0 mL, 0.4 M) and 3 M aqueous K₃PO₄ (4.0 mL, 5 eq.) at 45 °C for 21 h. Brine (40 mL) and Et₂O (40 mL) were used in the workup. Alkene **6d** was isolated as a pale yellow oil (557 mg, 95% yield).

TLC (hexanes:EtOAc 9:1)

R_f = 0.50, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 7.86 (d, *J* = 8.0 Hz, 1H), 7.56 (d, *J* = 8.0 Hz, 1H), 7.45 (t, *J* = 7.5 Hz, 1H), 7.26 (t, *J* = 7.5 Hz, 1H), 7.14 (d, *J* = 16.0 Hz, 1H), 6.11 (dd, *J* = 16.0, 7.0 Hz, 1H), 3.92 (s, 3H), 2.26-2.15 (m, 1H), 1.90-1.83 (m, 2H), 1.83-1.74 (m, 2H), 1.74-1.66 (m, 1H), 1.42-1.29 (m, 2H), 1.28-1.16 (m, 3H).

¹³C-NMR (125 MHz, CDCl₃)

δ 168.1, 139.9, 139.6, 131.9, 130.3, 128.2, 127.1, 126.4, 126.1, 52.0, 41.3, 32.9, 26.2, 26.1.


HRMS (ESI+)

Calculated for C₁₆H₂₀O₂ (M+H)⁺: 245.1536

Found: 245.1541

IR (thin film, cm⁻¹)

2923, 2850, 1719, 1448, 1247, 1126, 1075, 966, 903, 725, 649



Methyl (E)-2-(3-phenylprop-1-en-1-yl)benzoate 6e. Following the “general procedure for the synthesis of substrates 6a-h”, methyl 2-bromobenzoate **SI-1a** (645 mg, 3.0 mmol, 1.0 eq.), trans-3-phenyl-1-propenylboronic acid pinacol ester **SI-8** (806 mg, 3.3 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (118 mg, 0.15 mmol, 5 mol%) were reacted in THF (10 mL, 0.3 M) and 3 M aqueous K₃PO₄ (5.0 mL, 5 eq.) at 45 °C for 17 h. Brine (40 mL) and Et₂O (40 mL) were used in the workup. Alkene **6e** was isolated as a pale yellow oil (740 mg, 98% yield).

TLC (hexanes:EtOAc 6:1)

R_f = 0.59, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 7.88 (d, *J* = 7.5 Hz, 1H), 7.56 (d, *J* = 7.5 Hz, 1H), 7.45 (t, *J* = 7.0 Hz, 1H), 7.38-7.22 (m, 7H), 6.28 (dt, *J* = 15.5, 6.5 Hz, 1H), 3.91 (s, 3H), 3.62 (d, *J* = 6.5 Hz, 2H).

¹³C-NMR (125 MHz, CDCl₃)

δ 168.1, 140.1, 139.2, 132.0, 131.9, 130.4, 129.9, 128.7, 128.5, 128.3, 127.3, 126.8, 126.2, 52.1, 39.6.


HRMS (ESI+)

Calculated for C₁₇H₁₆O₂ (M+H)⁺: 253.1223


Found: 253.1235

IR (thin film, cm^{-1})

3062, 3027, 2950, 1719, 1433, 1293, 1251, 1130, 1082, 966, 744, 700



Methyl (*E*)-2-(3-methoxyprop-1-en-1-yl)benzoate 6f. Following the “general procedure for the synthesis of substrates 6a-h”, methyl 2-bromobenzoate **SI-1a** (905 mg, 4.2 mmol, 1.0 eq.), trans-3-methoxy-1-propenylboronic acid pinacol ester **SI-9** (1.0 g, 5.0 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (165 mg, 0.21 mmol, 5 mol%) were reacted in THF (10.5 mL, 0.4 M) and 3 M aqueous K_3PO_4 (7.0 mL, 5 eq.) at 45 °C for 23 h. Brine (40 mL) and Et_2O (40 mL) were used in the workup. Alkene **6f** was isolated as a pale yellow oil (860 mg, 99% yield). Characterization of this compound was consistent with previously reported data.⁷



trans-5-cyano-1-penten-1-ylboronic acid pinacol ester SI-11. In a glovebox, to a 7 mL vial charged with a stir bar was added dicyclohexyl borane (160 mg, 0.9 mmol, 15 mol%) and pinacol borane (0.96 mL, 6.6 mmol, 1.1 eq.). The vial was capped, removed from the glovebox and placed under a nitrogen atmosphere. The slurry was cooled to 0 °C in an ice bath. Hex-5-ynenitrile **SI-10** (0.63 mL, 6.0 mmol, 1.0 eq.) was added in one portion. The solution was stirred at 23 °C for 17 h. After this time, celite was added to quench the reaction. The crude reaction was dry loaded onto celite and purified by column chromatography on silica gel (hexanes:EtOAc 100:0 → 80:20) to afford the pinacol ester **SI-11** as a clear, colorless oil (1.0 g, 75% yield).

TLC (hexanes:EtOAc 9:1)

 $R_f = 0.17$, stained by KMnO_4 $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ 6.52 (dt, $J = 18.0, 6.5$ Hz, 1H), 5.49 (dt, $J = 18.0, 1.5$ Hz, 1H), 2.38-2.26 (m, 4H), 1.79 (p, 7.0 Hz, 2H), 1.26 (s, 12H). $^{13}\text{C-NMR}$ (125 MHz, CDCl_3) δ 150.9, 119.4, 83.2, 34.2, 24.8, 23.9, 16.5.


HRMS (ESI+)

Calculated for $\text{C}_{12}\text{H}_{20}\text{BNO}_2$ ($\text{M}+\text{H}$)⁺: 222.1662

Found: 222.1666

IR (thin film, cm^{-1})

2978, 2934, 1638, 1364, 1352, 1321, 1142, 969, 849



methyl (*E*)-2-(5-cyanopent-1-en-1-yl)benzoate **6g.** Following the “general procedure for the synthesis of substrates 6a-h”, methyl 2-bromobenzoate **SI-1a** (538 mg, 2.5 mmol, 1.0 eq.), *trans*-5-cyano-1-penten-1-ylboronic acid pinacol ester **SI-11** (608 mg, 2.8 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (98 mg, 0.13 mmol, 5 mol%) were reacted in THF (6.3 mL, 0.4 M) and 3 M aqueous K_3PO_4 (4.0 mL, 5 eq.) at 45 °C for 20.5 h. Brine (40 mL) and Et_2O (40 mL) were used in the workup. Alkene **6g** was isolated as a pale yellow oil (544 mg, 95% yield).

TLC (hexanes:EtOAc 9:1)

 $R_f = 0.13$, stained by KMnO_4 $^1\text{H-NMR}$ (500 MHz, CDCl_3)

δ 7.87 (dd, $J = 8.0, 1.5$ Hz, 1H), 7.51 (d, $J = 8.0$ Hz, 1H), 7.45 (dt, $J = 7.0, 1.5$ Hz, 1H), 7.29 (dt, $J = 7.5, 1.5$ Hz, 1H), 7.20 (d, $J = 16.0$ Hz, 1H), 6.02 (dt, $J = 16.0, 7.0$ Hz, 1H), 3.90 (s, 3H), 2.46-2.38 (m, 4H), 1.88 (p, $J = 7.0$ Hz, 2H).

 $^{13}\text{C-NMR}$ (125 MHz, CDCl_3)

δ 167.8, 139.1, 132.1, 131.0, 130.4, 130.3, 128.1, 127.3, 127.0, 119.7, 52.1, 31.8, 24.9, 16.4.


HRMS (ESI+)

Calculated for $\text{C}_{14}\text{H}_{15}\text{NO}_2$ ($\text{M}+\text{H}$)⁺: 230.1176

Found: 230.1183

IR (thin film, cm^{-1})

3065, 2998, 2950, 1715, 1433, 1293, 1248, 1129, 1074, 965, 746, 706



(*S,E*)-2-(3,7-dimethyloct-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane **SI-14.** In a glovebox, to a 100 mL round bottom flask charged with a stir bar was added chromium (II) chloride (3.6 g, 29.6 mmol, 8.0 eq). The round bottom was sealed with a septum, removed from the glovebox, and placed under a nitrogen atmosphere. To the flask was added THF (35 mL),

followed by a solution of aldehyde **SI-12** (526 mg, 3.7 mmol, 1.0 eq) and pinacol ester **SI-13** (1.6 g, 7.4 mmol, 2.0 eq) in THF (10 mL). To the resulting suspension was slowly dropwise added a solution of lithium iodide (2.0 g, 15 mmol, 4.0 eq) in THF (5 mL). The resulting suspension was stirred at 23 °C, under a nitrogen atmosphere, in a reduced light environment (shielded with aluminum foil) for 18 h. After this time, the crude reaction was poured into a separatory funnel containing H₂O (100 mL) and hexanes (75 mL). After shaking, the organic layer was removed and the aqueous layer was extracted with hexanes (2 x 50 mL). The combined organic layers were dried over MgSO₄, filtered, and dry loaded onto celite for purification by column chromatography on silica gel (hexanes:EtOAc 100:0 → 90:10) to afford pinacol ester **SI-14** as a clear, colorless oil (603 mg, 61% yield).

¹H-NMR (500 MHz, CDCl₃)

δ 6.53 (dd, *J* = 18.0, 8.0 Hz, 1H), 5.38 (d, *J* = 18.0 Hz, 1H), 2.25-2.15 (m, 1H), 1.57-1.47 (m, 1H), 1.38-1.23 (m, 4H), 1.28 (s, 12H), 1.20-1.11 (m, 2H), 1.00 (d, *J* = 6.5 Hz, 3H), 0.86 (d, *J* = 6.5 Hz, 6H).

¹³C-NMR (125 MHz, CDCl₃)

δ 160.2, 83.0, 39.5, 39.0, 36.3, 27.9, 25.0, 24.8, 22.7, 19.5.

HRMS (ESI+)


Calculated for C₁₆H₃₁BO₂ (M+H)⁺: 267.2493

Found: 267.2501

IR (thin film, cm⁻¹)

2977, 2956, 2927, 2869, 1637, 1467, 1397, 1389, 1363, 1318, 1268, 1215, 1165, 1145, 999, 970, 901, 850, 729, 650

[α]_D²³ +12.8 (*c* 1.0, CHCl₃)



methyl (S,E)-2-(3,7-dimethyloct-1-en-1-yl)benzoate 6h. Following the “general procedure for the synthesis of substrates 6a-h”, methyl 2-bromobenzoate **SI-1a** (426 mg, 2.0 mmol, 1.0 eq.), (S,E)-2-(3,7-dimethyloct-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane **SI-14** (580 mg, 2.2 mmol, 1.1 eq.), and 2nd generation XPhosPd cycle (78 mg, 0.10 mmol, 5 mol%) were reacted in THF (5.0 mL, 0.4 M) and 3 M aqueous K₃PO₄ (3.3 mL, 5 eq.) at 40 °C for 23 h. Brine (40 mL) and Et₂O (40 mL) were used in the workup. Alkene **6h** was isolated as a pale yellow oil (525 mg, 96% yield).

TLC (hexanes:EtOAc 4:1)

R_f = 0.73, stained by KMnO₄

$^1\text{H-NMR}$ (500 MHz, CDCl_3)

δ 7.86 (d, $J = 7.5$ Hz, 1H), 7.56 (d, $J = 7.5$ Hz, 1H), 7.45 (t, $J = 6.5$ Hz, 1H), 7.27 (t, $J = 7.0$ Hz, 1H), 7.12 (d, $J = 16.0$ Hz, 1H), 6.02 (dd, $J = 16.0, 8.0$ Hz, 1H), 3.91 (s, 3H), 2.42-2.32 (m, 1H), 1.61-1.51 (sept, $J = 6.5$ Hz, 1H), 1.43-1.31 (m, 4H), 1.24-1.16 (m, 2H), 1.11 (d, $J = 7.0$ Hz, 3H), 0.89 (d, $J = 6.5$ Hz, 6H).

$^{13}\text{C-NMR}$ (125 MHz, CDCl_3)

δ 168.1, 139.9, 139.8, 131.9, 130.3, 128.2, 127.2, 126.7, 126.4, 51.9, 39.1, 37.4, 37.3, 28.0, 25.1, 22.7, 20.6.

HRMS (ESI+)


Calculated for $\text{C}_{18}\text{H}_{26}\text{O}_2$ ($\text{M}+\text{H}$) $^+$: 275.2006
Found: 275.2006

IR (thin film, cm^{-1})

2952, 2925, 2868, 1722, 1481, 1459, 1433, 1292, 1246, 1206, 1189, 1126, 1076, 967, 749, 707

$[\alpha]_{\text{D}}^{23} +24.2$ (c 1.0, CHCl_3)


V. Table 2. Fluorolactonization of aryl substituted substrates



General procedure for the synthesis of products **5a-o**.

To a 7 mL low-density polyethylene vial with snap cap charged with a Teflon PTFE coated stir bar was added mCPBA (77%, 269 mg, 1.2 mmol, 1.2 eq.). The reaction vial was cooled in a dry ice/acetone bath to <-60 °C. To the cooled vial was added aryl iodide catalyst **2d** (56.0 mg, 0.10 mmol HF, 10 mol%) as a solution in CH_2Cl_2 (1.5 mL) followed by pyr·9HF (70% HF, 0.65 mL, 25 mmol HF, 25 eq. HF). The alkene **4a-o** (1.0 mmol) was added as a solution in CH_2Cl_2 (1.0 mL, 0.40 M total concentration). The tube was capped and transferred to a -50 °C cryocool with

vigorous stirring (vigorous stirring of the heterogeneous mixture is important to ensure reproducible conversion) at $-50\text{ }^{\circ}\text{C}$ for 24 h. After this time, the crude reaction suspension was quenched by being added to a cooled ($-78\text{ }^{\circ}\text{C}$) suspension of basic alumina (2.5 g) in CH_2Cl_2 (5.0 mL). The resulting suspension was warmed to $23\text{ }^{\circ}\text{C}$ and stirred at this temperature for 10 min. The suspension was filtered through a plug of basic alumina, eluting with CH_2Cl_2 . The solution was concentrated under reduced pressure. The resulting residue was dry loaded onto celite and purified by column chromatography on silica gel (hexanes:EtOAc 100:0 \rightarrow 80:20) to afford fluorolactone **5a-o**.



4-fluoro-3,8-dimethylisochroman-1-one 5a. Following the “general procedure for the synthesis of products 5a-o” on a 1 mmol scale, fluorolactone **5a** was isolated as a white solid (103 mg, 53% yield).

TLC (hexanes:EtOAc 1:1)

$R_f = 0.35$, stained by KMnO_4

$^1\text{H-NMR}$ (500 MHz, CDCl_3)

δ 7.53 (t, $J = 7.5$ Hz, 1H), 7.43 (d, $J = 7.5$ Hz, 1H), 7.34 (d, $J = 7.0$ Hz, 1H), 5.29 (d, $J = 50.0$ Hz, 1H), 4.65 (dq, $J = 27.0, 6.5$ Hz, 1H), 2.73 (s, 3H), 1.61 (d, $J = 7.0$ Hz, 3H).

$^{13}\text{C-NMR}$ (125 MHz, CDCl_3)

δ 163.2, 143.4 (d, $J = 2.5$ Hz), 135.8 (d, $J = 16.5$ Hz), 134.6 (d, $J = 3.5$ Hz), 133.2 (d, $J = 3.0$ Hz), 126.7 (d, $J = 3.5$ Hz), 122.9 (d, $J = 2.5$ Hz), 86.5 (d, $J = 179.5$ Hz), 74.9 (d, $J = 20.5$ Hz), 22.2, 16.1 (d, $J = 4.0$ Hz).

$^{19}\text{F-NMR}$ (470 MHz, CDCl_3)

δ -184.6 (dd, $J = 50.0, 27.0$ Hz).

HRMS (ESI+)

Calculated for $\text{C}_{11}\text{H}_{11}\text{FO}_2$ ($\text{M}+\text{H}$) $^+$: 195.0816

Found: 195.0823


IR (thin film, cm^{-1})

2989, 2941, 1716, 1255, 1241, 1217, 1117, 1070, 964, 937, 899, 811, 788, 703


$[\alpha]_D^{23} +123.6$ (*c* 1.0, CHCl₃)


96% *ee*, Chiral GC (β-Cyclosil, 60 °C to 180 °C, 10 psi); *t_R*(minor) = 47.7 min, *t_R*(major) = 49.2 min.

Racemic sample:



Enriched sample:





4-fluoro-3,7-dimethylisochroman-1-one 5b. Following the “general procedure for the synthesis of products 5a-o” on a 1 mmol scale, fluorolactone **5b** was isolated as a white solid (97 mg, 50% yield).

TLC (hexanes:EtOAc 3:1)

$R_f = 0.36$, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 8.00 (s, 1H), 7.49 (d, $J = 7.0$ Hz, 1H), 7.41 (dd, $J = 7.0, 3.0$ Hz, 1H), 5.29 (dd, $J = 50.0, 1.5$ Hz, 1H), 4.69 (dq, $J = 28.0, 6.5, 1.5$ Hz, 1H), 2.45 (d, $J = 3.0$ Hz, 3H), 1.63 (d, $J = 7.0$ Hz, 3H).

¹³C-NMR (125 MHz, CDCl₃)

δ 164.1, 141.7 (d, $J = 3.5$ Hz), 135.0 (d, $J = 3.0$ Hz), 131.9 (d, $J = 17.5$ Hz), 130.7 (d, $J = 2.5$ Hz), 128.8 (d, $J = 3.5$ Hz), 124.5 (d, $J = 2.5$ Hz), 85.3 (d, $J = 180.5$ Hz), 75.8 (d, $J = 23.0$ Hz), 21.3, 16.2 (d, $J = 5.0$ Hz).

¹⁹F-NMR (470 MHz, CDCl₃)

δ -182.0 (dd, $J = 50.0, 28.0$ Hz).

HRMS (ESI+)

Calculated for C₁₁H₁₁FO₂ (M+H)⁺: 195.0816

Found: 195.0824


IR (thin film, cm⁻¹)

2988, 2941, 1720, 1280, 1238, 1208, 1193, 1153, 1139, 1090, 1037, 946, 891, 843, 787, 589



$[\alpha]_D^{23} +67.4$ (c 1.0, CHCl₃)

93% *ee*, Chiral GC (β -Cyclosil, 60 °C to 180 °C, 10 psi); t_R (major) = 52.0 min, t_R (minor) = 52.3 min.

Racemic sample:



Enriched sample:



4-fluoro-3,6-dimethylisochroman-1-one 5c. Following the “general procedure for the synthesis of products 5a-o” on a 1 mmol scale, fluorolactone **5c** was isolated as a white solid (124 mg, 64% yield).

TLC (hexanes:EtOAc 3:1)

$R_f = 0.29$, stained by KMnO_4

¹H-NMR (500 MHz, CDCl₃)

δ 8.05 (d, *J* = 8.0 Hz, 1H), 7.41 (d, *J* = 8.0 Hz, 1H), 7.31 (s, 1H), 5.26 (dd, *J* = 50.0, 1.5 Hz, 1H), 4.69 (dq, *J* = 27.5, 6.5, 1.5 Hz, 1H), 2.46 (s, 3H), 1.62 (d, *J* = 6.5 Hz, 3H).

¹³C-NMR (125 MHz, CDCl₃)

δ 164.1, 145.5 (d, *J* = 3.0 Hz), 134.6 (d, *J* = 17.0 Hz), 132.0 (d, *J* = 3.5 Hz), 130.4 (d, *J* = 2.5 Hz), 129.3 (d, *J* = 3.0 Hz), 122.0 (d, *J* = 2.5 Hz), 85.5 (d, *J* = 181.5 Hz), 75.7 (d, *J* = 22.5 Hz), 21.7, 16.1 (d, *J* = 5.0 Hz).

¹⁹F-NMR (470 MHz, CDCl₃)

δ -183.1 (dd, *J* = 49.5, 28.0 Hz).

HRMS (ESI+)

Calculated for C₁₁H₁₁FO₂ (M+H)⁺: 195.0816

Found: 195.0825


IR (thin film, cm⁻¹)

2986, 2943, 1729, 1615, 1274, 1237, 1135, 1094, 1037, 944, 927, 907, 892, 881, 852, 780, 729, 709, 697, 639

[α]_D²³ +56.0 (*c* 1.0, CHCl₃)

94% *ee*, Chiral GC (β-Cyclosil, 60 °C to 180 °C, 10 psi); t_R(major) = 54.6 min, t_R(minor) = 55.8 min.

Racemic sample:



Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	54.607	BB	0.1133	245.88181	27.04622	50.14268
2	55.795	BB	0.1247	244.48247	26.24483	49.85732

Totals : 490.36427 53.29106

Calculated for $C_{11}H_{11}FO_2$ (M+H)⁺: 195.0816
 Found: 195.0820


IR (thin film, cm^{-1})

2991, 2942, 1717, 1275, 1172, 1160, 1137, 1080, 1038, 985, 949, 763


$[\alpha]_D^{23} +48.4$ (*c* 1.0, $CHCl_3$)


66% *ee*, Chiral GC (β -Cyclosil, 60 °C to 180 °C, 10 psi); t_R (major) = 56.0 min, t_R (minor) = 56.5 min.

Racemic sample:



Enriched sample:





4-fluoro-3-methyl-7-(trifluoromethoxy)isochroman-1-one 5e. Following the “general procedure for the synthesis of products 5a-o” on a 1 mmol scale, fluorolactone **5e** was isolated as a white solid (145 mg, 55% yield).

TLC (hexanes:EtOAc 3:1)

R_f = 0.26, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 8.02 (s, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.53 (d, J = 8.5 Hz, 1H), 5.35 (d, J = 49.5 Hz, 1H), 4.74 (dq, J = 27.5, 6.5 Hz, 1H), 1.65 (d, J = 6.5 Hz, 3H).

¹³C-NMR (125 MHz, CDCl₃)

δ 162.5, 151.6 (app sextet, J = 2.0 Hz), 133.0 (d, J = 17.5 Hz), 130.9 (d, J = 3.0 Hz), 126.8 (d, J = 2.0 Hz), 126.5, 122.1, 120.3 (q, J = 258.0 Hz), 84.4 (d, J = 182.0 Hz), 76.0 (dd, J = 22.0, 3.0 Hz), 16.0 (d, J = 5.0 Hz).

¹⁹F-NMR (470 MHz, CDCl₃)

δ -58.0, -183.1 (dd, J = 49.0, 27.0 Hz).

HRMS (ESI+)

Calculated for C₁₁H₈F₄O₃ (M+H)⁺: 265.0482

Found: 265.0476


IR (thin film, cm⁻¹)

2996, 2945, 1725, 1252, 1204, 1164, 1132, 1106, 1085, 1038, 990, 961, 931, 897, 880, 836, 786, 587



$[\alpha]_D^{23}$ +62.6 (c 1.0, CHCl₃)

89% *ee*, Chiral GC (β -Cyclosil, 60 °C to 180 °C, 10 psi); t_R (major) = 39.8 min, t_R (minor) = 40.6 min.

Racemic sample:



Enriched sample:



7-bromo-4-fluoro-3-methylisochroman-1-one 5f. Following the “general procedure for the synthesis of products 5a-o” on a 1 mmol scale, fluorolactone **5f** was isolated as a white solid (124 mg, 48% yield).

TLC (hexanes:EtOAc 3:1)

$R_f = 0.34$, stained by KMnO_4

¹H-NMR (500 MHz, CDCl₃)

δ 8.33 (bs, 1H), 7.84-7.81 (m, 1H), 7.42 (dd, *J* = 8.0, 2.5 Hz, 1H), 5.32 (dd, *J* = 49.5, 1.5 Hz, 1H), 4.72 (dq, *J* = 28.0, 7.0, 1.5 Hz, 1H), 1.65 (dd, *J* = 6.5, 1.0 Hz, 3H).

¹³C-NMR (125 MHz, CDCl₃)

δ 162.5, 137.3 (d, *J* = 3.0 Hz), 133.4 (d, *J* = 3.0 Hz), 133.3 (d, *J* = 17.5 Hz), 130.4 (d, *J* = 3.0 Hz), 126.3 (d, *J* = 2.0 Hz), 122.5 (d, *J* = 4.5 Hz), 84.7 (d, *J* = 182.0), 75.8 (d, *J* = 22.0 Hz), 16.0 (d, *J* = 4.5 Hz).

¹⁹F-NMR (470 MHz, CDCl₃)

δ -183.4 (dd, *J* = 49.5, 27.5 Hz).

HRMS (ESI+)

Calculated for C₁₀H₈BrFO₂ (M+H)⁺: 258.9764

Found: 258.9759


IR (thin film, cm⁻¹)

3084, 2990, 2942, 1723, 1418, 1283, 1254, 1228, 1136, 1099, 1072, 1036, 983, 942, 896, 875, 830, 788, 704, 583, 526

[α]_D²³ +55.0 (*c* 1.0, CHCl₃)

86% *ee*, Chiral GC (β-Cyclosil, 60 °C to 180 °C, 10 psi); t_R(major) = 67.5 min, t_R(minor) = 68.6 min.

Racemic sample:





Signal 2: FID2 B, Back Signal

Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	67.624	BB	0.1302	525.79370	48.59820	49.91754
2	68.724	BB	0.1222	527.53082	52.43005	50.08246

Totals : 1053.32452 101.02824

Enriched sample:



7-chloro-4-fluoro-3-methylisochroman-1-one 5g. Following the “general procedure for the synthesis of products 5a-o” on a 1 mmol scale, fluorolactone **5g** was isolated as a white solid (128 mg, 60% yield).

TLC (hexanes:EtOAc 3:1)

$R_f = 0.26$, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 8.15 (d, $J = 2.0$ Hz, 1H), 7.66 (dq, $J = 8.5, 1.5$ Hz, 1H), 7.49 (dd, $J = 8.5, 2.5$ Hz, 1H), 5.32 (dd, $J = 49.5, 1.5$ Hz, 1H), 4.72 (dq, $J = 27.5, 6.5, 1.5$ Hz, 1H), 1.64 (dd, $J = 6.5, 1.0$ Hz, 3H).

¹³C-NMR (125 MHz, CDCl₃)

δ 162.6, 137.6 (d, $J = 4.5$ Hz), 134.4 (d, $J = 3.0$ Hz), 132.9 (d, $J = 18.5$ Hz), 130.3 (d, $J = 2.5$ Hz), 130.3 (d, $J = 3.5$ Hz), 126.3 (d, $J = 2.0$ Hz), 84.6 (d, $J = 182.5$ Hz), 75.9 (d, $J = 22.0$ Hz), 16.0 (d, $J = 5.0$ Hz).

¹⁹F-NMR (470 MHz, CDCl₃)

δ -183.2 (dd, J = 49.5, 27.5 Hz).

HRMS (ESI+)

Calculated for $C_{10}H_8ClFO_2$ (M+H)⁺: 215.0270

Found: 215.0278


IR (thin film, cm^{-1})

2999, 2943, 1729, 1285, 1256, 1227, 1134, 1077, 939, 907, 895, 878, 826, 782, 729, 705, 665, 584, 529


$[\alpha]_D^{23}$ +69.0 (c 1.0, $CHCl_3$)

86% *ee*, Chiral GC (β -Cyclosil, 60 °C to 180 °C, 10 psi); t_R (major) = 58.1 min, t_R (minor) = 59.2 min.

Racemic sample:




Enriched sample:



Signal 2: FID2 B, Back Signal

Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	58.055	MM	0.1635	432.26938	44.06221	93.04374
2	59.177	MM	0.1543	32.31788	3.49147	6.95626
Totals :				464.58726	47.55368	



4,8-difluoro-3-methylisochroman-1-one 5h. Following the “general procedure for the synthesis of products 5a-o” on a 1 mmol scale, fluorolactone **5h** was isolated as a white solid (133 mg, 67% yield).

TLC (hexanes:EtOAc 4:1)

R_f = 0.10, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 7.72-7.64 (m, 1H), 7.38-7.27 (m, 2H), 5.34 (dt, J = 49.5, 2.0 Hz, 1H), 4.70 (dq, J = 27.5, 7.0, 1.5 Hz, 1H), 1.62 (dd, J = 6.5, 1.0 Hz, 3H).

¹³C-NMR (125 MHz, CDCl₃)

δ 163.7, 160.5 (d, J = 270.0, 7.0 Hz), 136.9 (d, J = 17.0 Hz), 135.9 (dd, J = 10.0, 3.0 Hz), 124.6 (t, J = 4.0 Hz), 119.8 (dd, J = 21.5, 3.5 Hz), 113.0 (d, J = 7.0 Hz), 85.1 (dd, J = 183.0, 2.5 Hz), 75.4 (d, J = 22.0 Hz), 15.9 (d, J = 4.0 Hz).

¹⁹F-NMR (470 MHz, CDCl₃)

δ -107.4, -185.1 (dd, J = 52.5, 26.5 Hz).

HRMS (ESI+)

Calculated for C₁₀H₈F₂O₂ (M+H)⁺: 199.0565

Found: 199.0571


IR (thin film, cm⁻¹)

2994, 2944, 1728, 1475, 1251, 1108, 1041, 978, 939, 896, 820, 798, 728, 696, 591



$[\alpha]_D^{23}$ +89.2 (c 1.0, CHCl₃)

83% *ee*, Chiral GC (β -Cyclosil, 60 °C to 180 °C, 10 psi); t_R (minor) = 53.4 min, t_R (major) = 53.9 min.

Racemic sample:



Enriched sample:



4,7-difluoro-3-methylisochroman-1-one 5i. Following the “general procedure for the synthesis of products 5a-o” on a 1 mmol scale, fluorolactone **5i** was isolated as a white solid (113 mg, 57% yield).

TLC (hexanes:EtOAc 3:1)

$R_f = 0.26$, stained by KMnO_4

$^1\text{H-NMR}$ (500 MHz, CDCl_3)

δ 7.84 (dd, $J = 8.5, 2.5$ Hz, 1H), 7.55 (ddd, $J = 8.5, 5.0, 2.5$ Hz, 1H), 7.39 (ddd, $J = 8.5, 2.5, 1.0$ Hz, 1H), 5.32 (dd, $J = 49.5, 1.5$ Hz, 1H), 4.72 (dq, $J = 28.0, 6.5, 1.5$ Hz, 1H), 1.64 (dd, $J = 7.0, 1.0$ Hz, 3H).

$^{13}\text{C-NMR}$ (125 MHz, CDCl_3)

δ 164.0 (dd, $J = 252.5, 3.5$ Hz), 162.8 (dd, $J = 2.5, 1.0$ Hz), 131.2 (dd, $J = 7.5, 3.0$ Hz), 130.8 (dd, $J = 18.0, 3.0$ Hz), 127.0 (dd, $J = 8.5, 2.0$ Hz), 121.7 (dd, $J = 22.5, 3.0$ Hz), 117.1 (dd, $J = 23.5, 2.5$ Hz), 84.5 (dd, $J = 182.0, 2.5$ Hz), 76.1 (dd, $J = 22.5, 2.0$ Hz), 16.1 (d, $J = 5.0$ Hz).

$^{19}\text{F-NMR}$ (470 MHz, CDCl_3)

δ -107.1 (m), -181.8 (ddd, $J = 49.0, 28.0, 8.0$ Hz).

HRMS (ESI+)

Calculated for $\text{C}_{10}\text{H}_8\text{F}_2\text{O}_2$ (M+H) $^+$: 199.0565

Found: 199.0561


IR (thin film, cm^{-1})

3075, 3006, 2949, 1721, 1505, 1439, 1296, 1275, 1236, 1217, 1129, 1076, 1033, 944, 901, 893, 850, 830, 787, 694, 591, 534

$[\alpha]_D^{23} +80.2$ (c 1.0, CHCl_3)

93% *ee*, Chiral GC (β -Cyclosil, 60 °C to 180 °C, 10 psi); t_R (major) = 41.3 min, t_R (minor) = 42.4 min.

Racemic sample:




Signal 2: FID2 B, Back Signal


Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	41.234	BB	0.1085	217.18713	27.87222	50.00758
2	42.335	BB	0.1140	217.12128	26.71702	49.99242
Totals :				434.30841	54.58924	

Enriched sample:

FID2 B, Back Signal (EMW\DEF_GC 2015-08-18 15-49-25\EMW-531A-IV-187-ENT.D)



Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	41.305	MM	0.1365	814.52423	99.46216	96.38617
2	42.350	MM	0.1337	30.53919	3.80829	3.61383
Totals :				845.06342	103.27045	



4,6-difluoro-3-methylisochroman-1-one 5j. Following the “general procedure for the synthesis of products 5a-o” on a 1 mmol scale, fluorolactone **5j** was isolated as a white solid (121 mg, 61% yield).

TLC (hexanes:EtOAc 3:1)

$R_f = 0.25$, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 8.20 (dd, $J = 8.5, 5.5$ Hz, 1H), 7.29 (tt, $J = 8.5, 2.5$ Hz, 1H), 7.21 (dt, $J = 8.0, 2.5$ Hz, 1H), 5.30 (dd, $J = 49.5, 1.5$ Hz, 1H), 4.72 (dq, $J = 27.5, 7.0, 1.5$ Hz, 1H), 1.61 (dd, $J = 7.0, 1.0$ Hz, 3H).

¹³C-NMR (125 MHz, CDCl₃)

δ 165.9 (dd, $J = 258.0, 3.5$ Hz), 162.8, 137.3 (dd, $J = 17.0, 8.5$ Hz), 133.6 (dd, $J = 9.5, 2.5$ Hz), 121.0 (t, $J = 3.0$ Hz), 118.7 (dd, $J = 22.5, 3.5$ Hz), 115.6 (dd, $J = 23.0, 3.5$ Hz), 84.9 (d, $J = 183.0$ Hz), 75.6 (d, $J = 22.0$ Hz), 15.9 (d, $J = 5.0$ Hz).

^{19}F -NMR (470 MHz, CDCl_3)

δ -101.9 (m), -184.5 (dd, $J = 49.5, 27.0$ Hz).

HRMS (ESI+)

Calculated for $\text{C}_{10}\text{H}_8\text{F}_2\text{O}_2$ (M+H) $^+$: 199.0565

Found: 199.0572


IR (thin film, cm^{-1})

3081, 2991, 2950, 1741, 1613, 1361, 1298, 1267, 1254, 1119, 1100, 953, 871, 694

$[\alpha]_{\text{D}}^{23} +57.4$ (c 1.0, CHCl_3)

80% *ee*, Chiral GC (β -Cyclosil, 60 °C to 180 °C, 10 psi); t_{R} (major) = 42.9 min, t_{R} (minor) = 43.7 min.

Racemic sample:



Enriched sample:


IR (thin film, cm^{-1})

3069, 3000, 2950, 1724, 1477, 1363, 1274, 1251, 1171, 1158, 1134, 1107, 1034, 965, 922, 879, 852, 763


$[\alpha]_D^{23} +27.4$ (*c* 1.0, CHCl_3)


30% *ee*, Chiral GC (β -Cyclosil, 60 °C to 180 °C, 10 psi); $t_R(\text{minor}) = 41.1$ min, $t_R(\text{major}) = 41.5$ min.

Racemic sample:



Enriched sample:





4-fluoro-3-methyl-7-(trifluoromethyl)isochroman-1-one 5I. Following the “general procedure for the synthesis of products 5a-o” on a 1 mmol scale, fluorolactone **5I** was isolated as a white solid (149 mg, 60% yield).

TLC (hexanes:EtOAc 2:1)

R_f = 0.43, stained by KMnO_4

$^1\text{H-NMR}$ (500 MHz, CDCl_3)

δ 8.47 (s, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.69 (dd, J = 8.0, 1.5 Hz, 1H), 5.40 (dd, J = 49.0, 1.5 Hz, 1H), 4.76 (dq, J = 26.0, 6.5, 2.0 Hz, 1H), 1.66 (dd, J = 6.5, 1.0 Hz, 3H).

$^{13}\text{C-NMR}$ (125 MHz, CDCl_3)

δ 162.4, 137.8 (d, J = 17.0 Hz), 133.7 (dd, J = 34.0, 3.5 Hz), 130.8 (m), 129.5 (d, J = 3.5 Hz), 127.6 (m), 125.6 (d, J = 2.5 Hz), 123.1 (d, J = 272.0 Hz), 84.4 (d, J = 183.0 Hz), 75.7 (d, J = 22.0 Hz), 15.9 (d, J = 4.5 Hz).

$^{19}\text{F-NMR}$ (470 MHz, CDCl_3)

δ -63.2 (d, J = 2.0 Hz), -185.1 (dd, J = 48.0, 26.5 Hz).

HRMS (ESI+)

Calculated for $\text{C}_{11}\text{H}_8\text{F}_4\text{O}_2$ ($\text{M}+\text{H}$)⁺: 249.0533

Found: 249.0535


IR (thin film, cm^{-1})

2994, 2917, 2849, 1729, 1331, 1251, 1234, 1172, 1126, 1098, 1069, 1039, 948, 885, 845, 634



$[\alpha]_D^{23}$ +39.4 (c 1.0, CHCl_3)

73% *ee*, Chiral GC (β -Cyclosil, 60 °C to 180 °C, 10 psi); t_R (major) = 40.2 min, t_R (minor) = 41.1 min.

Racemic sample:



Enriched sample:



4-fluoro-3-methyl-6-(trifluoromethyl)isochroman-1-one 5m. Following the “general procedure for the synthesis of products 5a-o” on a 1 mmol scale, fluorolactone **5m** was isolated as a white solid (109 mg, 44% yield).

TLC (hexanes:EtOAc 3:1)

$R_f = 0.41$, stained by KMnO_4

$^1\text{H-NMR}$ (500 MHz, CDCl_3)

δ 8.33 (d, $J = 8.0$ Hz, 1H), 7.89 (d, $J = 8.0$ Hz, 1H), 7.81 (s, 1H), 5.41 (dd, $J = 49.0, 1.5$ Hz, 1H), 4.77 (dq, $J = 27.5, 7.0, 2.0$ Hz, 1H), 1.67 (dd, $J = 7.0, 1.5$ Hz, 3H).

$^{13}\text{C-NMR}$ (125 MHz, CDCl_3)

δ 162.4, 135.8 (dq, $J = 33.0, 3.0$), 135.3 (d, $J = 18.0$ Hz), 131.2 (d, $J = 2.0$ Hz), 127.8, 127.0 (dp, $J = 274.0, 3.5$ Hz), 124.1, 121.9, 84.7 (d, $J = 183.0$ Hz), 75.8 (dd, $J = 22.0, 2.5$ Hz), 15.9 (d, $J = 5.0$ Hz).

$^{19}\text{F-NMR}$ (470 MHz, CDCl_3)

δ -63.3, -184.2 (dd, $J = 48.5, 26.5$ Hz).

HRMS (ESI+)

Calculated for $\text{C}_{11}\text{H}_8\text{F}_4\text{O}_2$ (M+H) $^+$: 249.0533

Found: 249.0537


IR (thin film, cm^{-1})

3100, 2994, 1737, 1337, 1322, 1297, 1268, 1197, 1185, 1154, 1129, 1097, 1067, 982, 941, 905, 883, 868, 798, 700

$[\alpha]_D^{23} +50.8$ (c 1.0, CHCl_3)

76% *ee*, Chiral GC (β -Cyclosil, 60 °C to 180 °C, 10 psi); t_R (major) = 40.3 min, t_R (minor) = 42.1 min.



Racemic sample:



Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	40.235	BB	0.1093	380.51321	48.81329	50.21573
2	41.998	BB	0.1255	377.24377	42.36752	49.78427

Totals : 757.75699 91.18081

Enriched sample:



methyl 4-fluoro-3-methyl-1-oxisochromane-7-carboxylate 5n. Following the “general procedure for the synthesis of products 5a-o” on a 1 mmol scale, fluorolactone **5n** was isolated as a white solid (83 mg, 35% yield).

TLC (hexanes:EtOAc 2:1)

R_f = 0.24, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 8.81 (s, 1H), 8.34 (dt, *J* = 8.0, 1.5 Hz, 1H), 7.62 (dd, *J* = 8.0, 2.0 Hz, 1H), 5.38 (dd, *J* = 49.0, 1.5 Hz, 1H), 4.75 (dq, *J* = 27.0, 7.0, 1.5 Hz, 1H), 3.96 (s, 3H), 1.64 (dd, *J* = 6.5, 1.0 Hz, 3H).

¹³C-NMR (125 MHz, CDCl₃)

δ 165.3, 162.9, 138.3 (d, *J* = 17.5 Hz), 135.0 (d, *J* = 3.0 Hz), 133.2 (d, *J* = 3.5 Hz), 131.7 (d, *J* = 2.5 Hz), 129.0 (d, *J* = 3.5 Hz), 125.1 (d, *J* = 2.0 Hz), 84.8 (d, *J* = 183.0 Hz), 75.6 (d, *J* = 21.5 Hz), 52.7, 15.8.

¹⁹F-NMR (470 MHz, CDCl₃)

δ -185.2 (dd, *J* = 50.0, 27.0 Hz).

HRMS (ESI+)

Calculated for $C_{12}H_{11}FO_4$ (M+H)⁺: 239.0714

Found: 239.0725


IR (thin film, cm^{-1})

2995, 2954, 1720, 1304, 1234, 1134, 1082, 1037, 989, 969, 944, 897, 770, 761, 731, 698, 584


$[\alpha]_D^{23} +64.6$ (*c* 1.0, $CHCl_3$)


70% *ee*, Chiral GC (β -Cyclosil, 60 °C to 200 °C, 10 psi); t_R (major) = 82.3 min, t_R (minor) = 82.7 min.

Racemic sample:



Enriched sample:





methyl 4-fluoro-3-methyl-1-oxisochromane-6-carboxylate 5o. Following the “general procedure for the synthesis of products 5a-o” on a 1 mmol scale, fluorolactone **5o** was isolated as a white solid (121 mg, 51% yield).

TLC (hexanes:EtOAc 1:1)

$R_f = 0.14$, stained by KMnO_4

$^1\text{H-NMR}$ (500 MHz, CDCl_3)

δ 8.22 (app s, 2H), 8.17-8.15 (m, 1H), 5.36 (dd, $J = 49.0, 1.5$ Hz, 1H), 4.73 (dq, $J = 27.5, 6.5, 1.5$ Hz, 1H), 3.94 (s, 3H), 1.63 (d, $J = 7.0$ Hz, 3H).

$^{13}\text{C-NMR}$ (125 MHz, CDCl_3)

δ 165.3, 162.9, 135.2 (d, $J = 2.5$ Hz), 134.8 (d, $J = 17.5$ Hz), 131.9 (d, $J = 3.5$ Hz), 130.6 (d, $J = 2.5$ Hz), 130.0 (d, $J = 3.0$ Hz), 128.1 (d, $J = 2.0$ Hz), 84.9 (d, $J = 181.5$ Hz), 75.8 (d, $J = 21.0$ Hz), 52.8, 16.0 (d, $J = 4.5$ Hz).

$^{19}\text{F-NMR}$ (470 MHz, CDCl_3)

δ -183.7 (dd, $J = 49.0, 27.5$ Hz).

HRMS (ESI+)

Calculated for $\text{C}_{12}\text{H}_{11}\text{FO}_4$ ($\text{M}+\text{H}$) $^+$: 239.0714

Found: 239.0720


IR (thin film, cm^{-1})

2997, 2956, 1720, 1267, 1232, 1202, 1132, 1113, 1084, 923, 907, 755, 747, 729, 713, 691

$[\alpha]_D^{23} +40.0$ (c 1.0, CHCl_3)

58% *ee*, Chiral GC (β -Cyclosil, 60 $^\circ\text{C}$ to 200 $^\circ\text{C}$, 10 psi); t_R (major) = 79.8 min, t_R (minor) = 81.3 min.


Racemic sample:



Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	79.844	BB	0.1443	406.93326	37.71641	49.75588
2	81.334	BB	0.1303	410.92630	41.08205	50.24412

Totals : 817.85956 78.79846


Enriched sample:




Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	79.813	MM	0.1741	254.40073	24.36075	78.93956
2	81.294	MM	0.1655	67.87207	6.83387	21.06044

Totals : 322.27280 31.19461

VI. Table 3. Fluorolactonization of alkene substituted substrates

**General procedure for the synthesis of products 7a-i.**

To a 7 mL low-density polyethylene vial with snap cap charged with a Teflon PTFE coated stir bar was added mCPBA (77%, 269 mg, 1.2 mmol, 1.2 eq.). The reaction vial was cooled in a dry ice/acetone bath to <-60 °C. To the cooled vial was added aryl iodide catalyst **2d** (56.0 mg, 0.10 mmol, 10 mol%) as a solution in CH₂Cl₂ (1.5 mL) followed by pyr•9HF (70% HF, 0.65 mL, 25 mmol HF, 25 eq. HF). The alkene **6a-h** (1.0 mmol) was added as a solution in CH₂Cl₂ (1.0 mL, 0.40 M total concentration). The tube was capped and transferred to a -50 °C cryocool with vigorous stirring (vigorous stirring of the heterogeneous mixture is important to ensure reproducible conversion) at -50 °C for 24 h. After this time, the crude reaction suspension was quenched by being added to a cooled (-78 °C) suspension of basic alumina (2.5 g) in CH₂Cl₂ (5.0 mL). The resulting suspension was warmed to 23 °C and stirred at this temperature for 10 min. The suspension was filtered through a plug of basic alumina, eluting with CH₂Cl₂. The solution was concentrated under reduced pressure. The resulting residue was dry loaded onto celite and purified by column chromatography on silica gel (hexanes:EtOAc 100:0 → 80:20) to afford fluorolactone **7a-i**.



4-fluoroisochroman-1-one 7a. Following the “general procedure for the synthesis of products 7a-i” on a 1 mmol scale, fluorolactone **7a** was isolated as a clear colorless oil (81.4 mg, 49% yield).

TLC (hexanes:EtOAc 4:1)

R_f = 0.16, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 8.21 (d, *J* = 7.5 Hz, 1H), 7.72 (t, *J* = 7.5 Hz, 1H), 7.64 (t, *J* = 7.5 Hz, 1H), 7.56 (d, *J* = 7.5 Hz, 1H), 5.59 (ap. dt, *J* = 49.5, 2.5 Hz, 1H), 4.86 (ddd, *J* = 16.1, 13.2 Hz, 3.4 Hz, 1H), 4.64 (ddd, *J* = 33.5, 12.5, 2.5 Hz, 1H).

¹³C-NMR (125 MHz, CDCl₃)

δ 163.1, 134.5 (d, *J* = 17.5 Hz), 134.4 (d, *J* = 3.0 Hz), 131.2 (d, *J* = 3.5 Hz), 130.5 (d, *J* = 2.0 Hz), 128.1 (d, *J* = 3.5 Hz), 124.8 (d, *J* = 2.0 Hz), 82.9 (d, *J* = 177.5 Hz), 69.7 (d, *J* = 24.5 Hz).

¹⁹F-NMR (470 MHz, CDCl₃)

δ -171.5 (ddd, *J* = 49.5, 34.0, 12.0 Hz).

HRMS (ESI+)

Calculated for C₉H₇FO₂ (M+H)⁺: 167.0503
 Found: 167.0499


IR (thin film, cm⁻¹)

2958, 1721, 1396, 1279, 1241, 1129, 1053, 1028, 961, 865, 767, 751, 716, 696, 606

[α]_D²³ +40.4 (*c* 1.0, CHCl₃)

87% *ee*, Chiral GC (β-Cyclosil, 60 °C to 180 °C, 10 psi); t_R(major) = 29.6 min, t_R(minor) = 29.8 min.



Racemic sample:



Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	29.627	BV	0.0501	419.01712	125.53122	49.60110
2	29.761	VB	0.0569	425.75674	114.73489	50.39890

Totals : 844.77386 240.26611

Enriched sample:



4-fluoro-3-propylisochroman-1-one 7b. Following the “general procedure for the synthesis of products 7a-i” on a 1 mmol scale, fluorolactone **7b** was isolated as a white solid (129 mg, 62% yield).

TLC (hexanes:EtOAc 4:1)

$R_f = 0.26$, stained by KMnO_4

$^1\text{H-NMR}$ (500 MHz, CDCl_3)

δ 8.19 (d, $J = 7.5$ Hz, 1H), 7.69 (tt, $J = 7.5, 1.5$ Hz, 1H), 7.62 (tdd, $J = 7.5, 2.0, 1.5$ Hz, 1H), 7.52 (ddd, $J = 7.5, 2.5, 1.5$ Hz, 1H), 5.37 (dd, $J = 49.5, 1.5$ Hz, 1H), 4.53 (dddd, $J = 29.0, 8.3, 5.5, 1.5$ Hz, 1H), 2.13-2.03 (m, 1H), 1.94-1.84 (m, 1H), 1.73-1.52 (m, 2H), 1.02 (t, $J = 7.5$ Hz, 3H).

$^{13}\text{C-NMR}$ (125 MHz, CDCl_3)

δ 163.9, 134.6 (d, $J = 17.0$ Hz), 134.2 (d, $J = 3.0$ Hz), 131.3 (d, $J = 3.5$ Hz), 130.4 (d, $J = 3.0$ Hz), 128.8 (d, $J = 3.5$ Hz), 125.1 (d, $J = 2.5$ Hz), 84.6 (d, $J = 180.5$ Hz), 79.2 (d, $J = 22.0$ Hz), 32.2 (d, $J = 3.5$ Hz), 18.2, 13.8.

$^{19}\text{F-NMR}$ (470 MHz, CDCl_3)

δ -182.2 (dd, $J = 49.5, 28.5$ Hz).

HRMS (ESI+)

Calculated for C₁₂H₁₃FO₂ (M+H)⁺: 209.0972

Found: 209.0978

IR (thin film, cm⁻¹)


2962, 2875, 1718, 1607, 1463, 1277, 1125, 979, 903, 718, 625

[α]_D²³ +46.2 (c 1.0, CHCl₃)

95% *ee*, Chiral HPLC (CHIRALPAK AD-H, 3% isopropanol in hexanes, 1.0 mL/min, λ = 230 nm); t_R(major) = 16.2 min, t_R(minor) = 20.1 min.

Racemic sample:

DAD1 C, Sig=230,4 Ref=450,100 (EMW\DEF_LC 2015-06-09 13-43-24\EMW-469A-IV-63-RAC2.D)




Signal 3: DAD1 C, Sig=230,4 Ref=450,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.028	BB	0.3528	1.14844e4	480.63147	48.9924
2	19.712	VB	0.4443	1.19568e4	395.92218	51.0076

Totals : 2.34412e4 876.55365

Enriched sample:


DAD1 C, Sig=230,4 Ref=450,100 (EMW\DEF_LC 2015-06-09 13-43-24\EMW-469A-IV-63-VIAL.D)



Signal 3: DAD1 C, Sig=230,4 Ref=450,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.211	BB	0.3573	7288.53760	302.28888	97.5958
2	20.066	BB	0.4193	179.54802	6.39947	2.4042

Totals : 7468.08562 308.68835



3-(3-chloropropyl)-4-fluoroisochroman-1-one 7c. Following the “general procedure for the synthesis of products 7a-i” on a 1 mmol scale, fluorolactone **7c** was isolated as a white solid (146 mg, 60% yield).

TLC (hexanes:EtOAc 4:1)

$R_f = 0.14$, stained by KMnO_4

$^1\text{H-NMR}$ (500 MHz, CDCl_3)

δ 8.20 (d, $J = 7.5$ Hz, 1H), 7.71 (tt, $J = 7.5, 1.5$ Hz, 1H), 7.64 (tt, $J = 7.5, 1.5$ Hz, 1H), 7.53 (d, $J = 7.5$ Hz, 1H), 5.38 (d, $J = 49.5$ Hz, 1H), 4.57 (dddd, $J = 28.0, 8.5, 4.4, 1.5$ Hz, 1H), 3.73-3.60 (m, 2H), 2.30-2.16 (m, 2H), 2.15-1.98 (m, 2H).

$^{13}\text{C-NMR}$ (125 MHz, CDCl_3)

δ 163.5, 134.4 (d, $J = 18.0$ Hz), 134.4 (d, $J = 3.0$ Hz), 131.4 (d, $J = 4.0$ Hz), 130.5 (d, $J = 3.0$ Hz), 128.8 (d, $J = 3.5$ Hz), 125.0 (d, $J = 2.0$ Hz), 84.9 (d, $J = 181.0$ Hz), 78.6 (d, $J = 21.0$ Hz), 44.5, 28.0, 27.9 (d, $J = 4.0$ Hz).

$^{19}\text{F-NMR}$ (470 MHz, CDCl_3)

δ -181.4 (dd, $J = 49.5, 28.5$ Hz).

HRMS (ESI+)

Calculated for $\text{C}_{12}\text{H}_{12}\text{ClFO}_2$ ($\text{M}+\text{H}$) $^+$: 243.0583

Found: 243.0588

IR (thin film, cm^{-1})


2961, 1732, 1275, 1240, 1124, 1092, 1029, 904, 765, 698

$[\alpha]_D^{23} +38.8$ (c 1.0, CHCl_3)

95% *ee*, Chiral HPLC (CHIRALPAK OD-H, 5% isopropanol in hexanes, 1.0 mL/min, $\lambda = 230$ nm); $t_R(\text{major}) = 27.9$ min, $t_R(\text{minor}) = 41.8$ min.



Racemic sample:

DAD1 C, Sig=230,4 Ref=450,100 (EMW\DEF_LC 2015-06-11 15-44-16\EMW-471A-IV-67-RAC-ODH.D)



Enriched sample:

DAD1 C, Sig=230,4 Ref=450,100 (EMW\DEF_LC 2015-06-11 15-44-16\EMW-471A-IV-67-1MMOL-ODH.D)



3-cyclohexyl-4-fluoroisochroman-1-one 7d. Following the “general procedure for the synthesis of products 7a-i” on a 1 mmol scale, fluorolactone **7d** was isolated as a white solid (144 mg, 58% yield).

TLC (hexanes:EtOAc 4:1)

$R_f = 0.37$, stained by KMnO_4

$^1\text{H-NMR}$ (500 MHz, CDCl_3)

δ 8.20 (d, $J = 7.5$ Hz, 1H), 7.70 (tt, $J = 7.5, 1.5$ Hz, 1H), 7.63 (t, $J = 7.5$ Hz, 1H), 7.52 (d, $J = 7.5$ Hz, 1H), 5.53 (d, $J = 49.5$ Hz, 1H), 4.17 (ddd, $J = 31.0, 9.0, 1.5$ Hz, 1H), 2.40-2.30 (m, 1H), 2.19-2.06 (m, 1H), 2.03-1.94 (m, 1H), 1.88-1.78 (m, 2H), 1.78-1.68 (m, 1H), 1.47-1.28 (m, 2H), 1.28-1.05 (m, 3H).

$^{13}\text{C-NMR}$ (125 MHz, CDCl_3)

δ 164.0, 134.5 (d, $J = 17.0$ Hz), 134.2 (d, $J = 3.0$ Hz), 131.3 (d, $J = 3.5$ Hz), 130.4 (d, $J = 3.0$ Hz), 129.0 (d, $J = 3.5$ Hz), 125.4 (d, $J = 2.0$ Hz), 83.7 (d, $J = 21.5$ Hz), 83.0 (d, $J = 180.5$ Hz), 37.9 (d, $J = 1.5$ Hz), 29.4, 28.2, 26.2, 25.7, 25.4.

$^{19}\text{F-NMR}$ (470 MHz, CDCl_3)

δ -181.9 (dd, $J = 49.5, 31.0$ Hz).

HRMS (ESI+)

Calculated for $\text{C}_{15}\text{H}_{17}\text{FO}_2$ (M+H) $^+$: 249.1285

Found: 249.1297

IR (thin film, cm^{-1})


2927, 2853, 1720, 1278, 1120, 905, 896, 765, 733, 699

$[\alpha]_D^{23} +37.2$ (c 1.0, CHCl_3)

92% *ee*, Chiral HPLC (CHIRALPAK OD-H, 5% isopropanol in hexanes, 1.0 mL/min, $\lambda = 230$ nm); t_R (major) = 10.0 min, t_R (minor) = 14.3 min.

Racemic sample:

DAD1 C, Sig=230,4 Ref=450,100 (EMW\DEF_LC 2015-06-11 15-44-16\EMW-472A-IV-69-RAC-ODH.D)




Signal 3: DAD1 C, Sig=230,4 Ref=450,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.109	BB	0.2422	1965.89319	124.51721	49.8751
2	14.288	BB	0.3427	1975.73926	88.42347	50.1249

Totals : 3941.63245 212.94068

Enriched sample:


DAD1 C, Sig=230,4 Ref=450,100 (EMW/DEF_LC 2015-06-11 15-44-16)EMW-472A-IV-69-1MMOL-ODH.



Signal 3: DAD1 C, Sig=230,4 Ref=450,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.012	MM	0.2734	1.19862e4	730.63019	96.2007
2	14.333	MM	0.4168	473.37363	18.92793	3.7993

Totals : 1.24595e4 749.55812



3-benzyl-4-fluoroisochroman-1-one 7e. Following the “general procedure for the synthesis of products 7a-i” on a 1 mmol scale, fluorolactone **7e** was isolated as a white solid (141 mg, 55% yield).

TLC (hexanes:EtOAc 4:1)

R_f = 0.34, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 8.21 (d, *J* = 7.0 Hz, 1H), 7.71-7.60 (m, 2H), 7.45 (m, 1H), 7.42-7.30 (m, 5H), 5.24 (dd, *J* = 49.5, 1.5 Hz, 1H), 4.71 (dddd, *J* = 28.3, 8.3, 6.8, 1.0 Hz, 1H), 3.40-3.32 (m, 2H).

^{13}C -NMR (125 MHz, CDCl_3)

δ 163.7, 135.3, 134.3 (d, $J=3.0$ Hz), 134.2, 131.4 (d, $J=3.5$ Hz), 130.5 (d, $J=2.5$ Hz), 129.7, 129.0 (d, $J=3.0$ Hz), 128.9, 127.3, 125.1 (d, $J=2.0$ Hz), 83.0 (d, $J=140.5$ Hz), 80.3 (d, $J=22.0$ Hz), 36.5 (d, $J=3.5$ Hz).

^{19}F -NMR (470 MHz, CDCl_3)

δ -182.2 (dd, $J=49.5, 28.5$ Hz).

HRMS (ESI+)

Calculated for $\text{C}_{16}\text{H}_{13}\text{FO}_2$ (M+H) $^+$: 257.0972

Found: 257.0981


IR (thin film, cm^{-1})

3063, 3030, 2951, 1729, 1267, 1239, 1122, 1089, 999, 898, 762, 735, 717, 696, 584

$[\alpha]_{\text{D}}^{23} +22.4$ (c 1.0, CHCl_3)

90% *ee*, Chiral HPLC (CHIRALPAK AD-H, 3% isopropanol in hexanes, 1.0 mL/min, $\lambda = 230$ nm); t_{R} (major) = 45.8 min, t_{R} (minor) = 56.6 min.

Racemic sample:




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	46.666	MM	1.4963	3367.69360	37.51128	49.6946
2	56.579	MM	1.8296	3409.08276	31.05462	50.3054

Totals : 6776.77637 68.56590


Enriched sample:

DAD1 C, Sig=230,4 Ref=450,100 (MJA\CRK 2015-06-13 14-34-00\EMW-479A-IV-83-ENT-ADH.D)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	45.782	MM	1.5592	4046.39917	43.25206	95.1278
2	56.583	MM	1.5617	207.24622	2.21174	4.8722

Totals : 4253.64539 45.46380



4-fluoro-3-(methoxymethyl)isochroman-1-one 7f. Following the “general procedure for the synthesis of products **7a-i**” on a 1 mmol scale, fluorolactone **7f** was isolated as a pale yellow solid (120 mg, 57% yield).

TLC (hexanes:EtOAc 4:1)

R_f = 0.16, stained by KMnO₄

¹H-NMR (500 MHz, CDCl₃)

δ 8.23 (d, *J* = 7.5 Hz, 1H), 7.73 (tt, *J* = 7.5, 1.5 Hz, 1H), 7.67 (tdd, *J* = 7.0, 2.0, 1.5 Hz, 1H), 7.57-7.54 (m, 1H), 5.58 (d, *J* = 49.5 Hz, 1H), 4.71 (dddd, *J* = 29.3, 7.8, 6.4, 1.5 Hz, 1H), 4.00-3.81 (m, 2H), 3.51 (s, 3H).

¹³C-NMR (125 MHz, CDCl₃)

δ 163.1, 134.5 (d, *J* = 3.0 Hz), 134.1 (d, *J* = 17.0 Hz), 131.5 (d, *J* = 4.5 Hz), 130.5 (d, *J* = 2.5 Hz), 129.0 (d, *J* = 3.5 Hz), 125.1 (d, *J* = 2.0 Hz), 82.7 (d, *J* = 180.0 Hz), 77.5 (d, *J* = 20.0 Hz), 69.4 (d, *J* = 5.0 Hz), 59.6.

¹⁹F-NMR (470 MHz, CDCl₃)

δ -182.7 (dd, *J* = 49.5, 29.0 Hz).

HRMS (ESI+)

Calculated for $C_{11}H_{11}FO_3$ (M+H)⁺: 211.0765

Found: 211.0772

IR (thin film, cm^{-1})


2929, 2820, 1729, 1270, 1236, 1205, 1112, 1090, 1028, 972, 901, 765, 725, 698

$[\alpha]_D^{23} +70.6$ (*c* 1.0, $CHCl_3$)

91% *ee*, Chiral HPLC (CHIRALPAK AD-H, 3% isopropanol in hexanes, 1.0 mL/min, $\lambda = 230$ nm); t_R (minor) = 24.0 min, t_R (major) = 28.2 min.

Racemic sample:

DAD1 C, Sig=230,4 Ref=450,100 (MJA\CRK 2015-06-13 14-34-00\EMW-480A-IV-85-RAC-ADH.D)




Signal 3: DAD1 C, Sig=230,4 Ref=450,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	24.780	BB	0.5717	2906.56152	75.73632	49.9255
2	29.117	BB	0.7200	2915.23145	59.25201	50.0745

Totals : 5821.79297 134.98833

Enriched sample:


DAD1 C, Sig=230,4 Ref=450,100 (MJA\CRK 2015-06-13 14-34-00\EMW-480A-IV-85-ENT-ADH.D)



Signal 3: DAD1 C, Sig=230,4 Ref=450,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	24.040	BB	0.5122	377.89301	10.80137	4.2904
2	28.183	BB	0.7616	8430.06152	166.79672	95.7096

Totals : 8807.95453 177.59809



4-(4-fluoro-1-oxoisochroman-3-yl)butanenitrile 7g. Following the “general procedure for the synthesis of products 7a-i” on a 1 mmol scale, fluorolactone **7g** was isolated as a white solid (95.6 mg, 41% yield).

TLC (hexanes:EtOAc 4:1)

R_f = 0.10, stained by KMnO_4

$^1\text{H-NMR}$ (500 MHz, CDCl_3)

δ 8.21 (d, J = 8.0 Hz, 1H), 7.72 (tt, J = 7.5, 1.5 Hz, 1H), 7.65 (tq, J = 7.0, 1.5 Hz, 1H), 7.54 (d, J = 7.0 Hz, 1H), 5.38 (dd, J = 50.0, 1.5 Hz, 1H), 4.57 (dddd, J = 28.0, 10.0, 3.9, 1.5 Hz, 1H), 2.59-2.41 (m, 2H), 2.36-2.22 (m, 1H), 2.20-2.02 (m, 2H), 2.01-1.88 (m, 1H).

$^{13}\text{C-NMR}$ (125 MHz, CDCl_3)

δ 163.3, 134.5 (d, J = 3.0 Hz), 134.2 (d, J = 17.0 Hz), 131.5 (d, J = 3.5 Hz), 130.5 (d, J = 3.0 Hz), 128.9 (d, J = 3.0 Hz), 124.8 (d, J = 2.5 Hz), 119.1, 84.8 (d, J = 182.0 Hz), 78.3 (d, J = 22.0 Hz), 29.5 (d, J = 3.5 Hz), 21.2, 17.0.

$^{19}\text{F-NMR}$ (470 MHz, CDCl_3)

δ -180.9 (dd, J = 50.0, 28.0 Hz).

HRMS (ESI+)

Calculated for $\text{C}_{13}\text{H}_{12}\text{FNO}_2$ ($\text{M}+\text{H}$)⁺: 234.0925

Found: 234.0932

IR (thin film, cm^{-1})


2949, 1728, 1607, 1272, 1241, 1125, 1092, 766, 698

$[\alpha]_D^{23}$ +39.8 (c 1.0, CHCl_3)

90% *ee*, Chiral HPLC (CHIRALPAK OD-H, 20% isopropanol in hexanes, 1.0 mL/min, λ = 238 nm); t_R (major) = 28.7 min, t_R (minor) = 38.2 min.

Racemic sample:

*DAD1, Sig=238.00, 2.00 Ref=off, EXT of EMW-508A-IV-141-ODH-RAC.D




Signal 5: DAD1, Sig=238.00, 2.00 Ref=off, EXT

Signal has been modified after loading from rawdata file!

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	28.641	MM	1.4218	1252.21875	14.67923	50.2501
2	37.786	MM	1.8016	1239.75171	11.46880	49.7499

Enriched sample:


*DAD1, Sig=238.00, 2.00 Ref=off, EXT of EMW-508A-IV-141-ODH-ENT.D



Signal 5: DAD1, Sig=238.00, 2.00 Ref=off, EXT

Signal has been modified after loading from rawdata file!

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	28.654	MM	1.4225	1730.69482	20.27771	95.1699
2	38.191	MM	1.5794	87.83695	9.26886e-1	4.8301



(3*S*,4*S*)-4-fluoro-3-((*S*)-6-methylheptan-2-yl)isochroman-1-one 7h. Following the “general procedure for the synthesis of products **7a-i**” on a 0.5 mmol scale, fluorolactone **7h** was isolated as a clear, colorless oil (68.5 mg, 49% yield) as a 6:1 mixture of diastereomers with **7i**.

TLC (hexanes:EtOAc 4:1)

$R_f = 0.35$, stained by KMnO_4

$^1\text{H-NMR}$ (500 MHz, CDCl_3) (Major diastereomer)

δ 8.21 (d, $J = 7.5$ Hz, 1H), 7.71 (tt, $J = 7.5, 1.5$ Hz, 1H), 7.64 (tdd, $J = 7.5, 2.5, 1.5$ Hz, 1H), 7.53 (ddd, $J = 7.5, 2.5, 1.0$ Hz, 1H), 5.53 (d, $J = 49.5$ Hz, 1H), 4.19 (ddd, $J = 31.0, 9.5, 1.5$ Hz, 1H), 2.32-2.23 (m, 1H), 1.96-1.88 (m, 1H), 1.61-1.53 (m, 1H), 1.51-1.41 (m, 1H), 1.35-1.20 (m, 4H), 1.15 (d, $J = 6.0$ Hz, 3H), 0.90 (dd, $J = 6.5, 2.0$ Hz, 6H).

$^{13}\text{C-NMR}$ (125 MHz, CDCl_3) (Major diastereomer)

δ 164.0, 134.6 (d, $J = 17.0$ Hz), 134.2 (d, $J = 2.5$ Hz), 131.3 (d, $J = 4.0$ Hz), 130.4 (d, $J = 3.0$ Hz), 129.0 (d, $J = 4.0$ Hz), 125.3 (d, $J = 2.0$ Hz), 83.4 (d, $J = 182.0$ Hz), 83.2 (d, $J = 21.5$ Hz), 39.1, 33.8, 32.4, 28.0, 24.0, 22.6 (d, $J = 35.5$ Hz), 14.8.

$^{19}\text{F-NMR}$ (470 MHz, CDCl_3) (Major diastereomer)

δ -182.5 (dd, $J = 49.5, 31.0$ Hz).

HRMS (ESI+)


Calculated for $\text{C}_{17}\text{H}_{23}\text{FO}_2$ ($\text{M}+\text{H}$) $^+$: 279.1755

Found: 279.1768

IR (thin film, cm^{-1})

2952, 2927, 2867, 1720, 1463, 1275, 1242, 1119, 1091, 995, 894, 765, 736, 698

$[\alpha]_D^{23} +43.6$ (c 1.0, CHCl_3)



(3*R*,4*R*)-4-fluoro-3-((*S*)-6-methylheptan-2-yl)isochroman-1-one 7i. Following the “general procedure for the synthesis of products **7a-i**” on a 0.5 mmol scale, and using *ent*-(**2d**) as the catalyst, fluorolactone **7i** was isolated as a clear, colorless oil (79.2 mg, 57% yield) as a 6:1 mixture of diastereomers with **7h**.

TLC (hexanes:EtOAc 4:1)

$R_f = 0.35$, stained by KMnO_4

$^1\text{H-NMR}$ (500 MHz, CDCl_3) (Major diastereomer)

δ 8.19 (d, $J = 7.5$ Hz, 1H), 7.69 (tt, $J = 7.5, 1.5$ Hz, 1H), 7.62 (tdd, $J = 7.5, 2.5, 1.5$ Hz, 1H), 7.51 (ddd, $J = 7.5, 2.5, 1.0$ Hz, 1H), 5.54 (d, $J = 50.0$ Hz, 1H), 4.19 (ddd, $J = 31.0,$

8.5, 1.5 Hz, 1H), 2.29-2.20 (m, 1H), 1.71-1.61 (m, 1H), 1.60-1.52 (m, 1H), 1.50-1.39 (m, 1H), 1.39-1.22 (m, 4H), 1.20 (d, $J = 6.5$ Hz, 3H), 0.89 (dd, $J = 6.5, 1.5$ Hz, 6H).

^{13}C -NMR (125 MHz, CDCl_3) (Major diastereomer)

δ 164.1, 134.7 (d, $J = 17.0$ Hz), 134.2 (d, $J = 3.0$ Hz), 131.3 (d, $J = 4.0$ Hz), 130.4 (d, $J = 3.0$ Hz), 128.9 (d, $J = 4.0$ Hz), 125.3 (d, $J = 2.0$ Hz), 83.6 (d, $J = 180.5$ Hz), 83.5 (d, $J = 22.5$ Hz), 39.0, 34.0, 32.3, 27.9, 24.4, 22.6 (d, $J = 34.0$ Hz), 15.5.

^{19}F -NMR (470 MHz, CDCl_3) (Major diastereomer)

δ -181.1 (dd, $J = 49.5, 31.5$ Hz).

HRMS (ESI+)

Calculated for $\text{C}_{17}\text{H}_{23}\text{FO}_2$ (M+H) $^+$: 279.1755


Found: 279.1768

IR (thin film, cm^{-1})

2952, 2932, 2868, 1720, 1464, 1347, 1275, 1243, 1120, 1091, 992, 895, 765, 736, 698

$[\alpha]_{\text{D}}^{23}$ -46.0 (c 1.0, CHCl_3)

VII. Scheme 2. Comparing electrophilic and nucleophilic fluorinating reagents



3-(fluoromethyl)isobenzofuran-1(3H)-one 9. To a 7 mL glass vial charged with a Teflon PTFE coated stir bar was added vinylbenzoic acid **8** (150 mg, 1.0 mmol, 1.0 eq.) and 2,6-dichloro-1-fluoropyridinium triflate (474 mg, 1.5 mmol, 1.5 eq.). The reaction vial was capped and placed under a nitrogen atmosphere. The vial was charged with CH_2Cl_2 (2.5 mL) and sealed under nitrogen. The vial was placed in a 40 °C heating block with stirring for 20 h. After this time, the crude reaction was dry loaded onto celite and purified by column chromatography on silica gel (hexanes:EtOAc 100:0 \rightarrow 60:40) to afford fluorolactone **9** as a clear, colorless oil (107 mg, 65% yield).

^1H -NMR (500 MHz, CDCl_3)

δ 7.95 (d, $J = 7.5$ Hz, 1H), 7.73 (t, $J = 7.5$ Hz, 1H), 7.60 (t, $J = 7.0$ Hz, 1H), 7.54 (d, $J = 7.5$ Hz, 1H), 5.66 (dt, $J = 18.5, 4.5$ Hz, 1H), 4.88-4.64 (m, 2H).

¹³C-NMR (125 MHz, CDCl₃)

δ 169.7, 145.1 (d, *J* = 4.5 Hz), 134.3, 130.0, 126.5, 126.1, 122.3, 82.4 (d, *J* = 179.0 Hz),
78.7 (d, *J* = 20.5 Hz).

¹⁹F-NMR (470 MHz, CDCl₃)

δ -229.0 (dt, *J* = 46.0, 18.0 Hz).


HRMS (ESI+)

Calculated for C₉H₇FO₂ (M+H)⁺: 167.0503

Found: 167.0503

IR (thin film, cm⁻¹)



2958, 1762, 1467, 1349, 1287, 1210, 1079, 1066, 1032, 982, 921, 743, 717, 696, 626



4-fluoroisochroman-1-one 7a. To a 7 mL low-density polyethylene vial with snap cap charged with a Teflon PTFE coated stir bar was added mCPBA (77%, 269 mg, 1.2 mmol, 1.2 eq.). The reaction vial was cooled in a dry ice/acetone bath to <-60 °C. To the cooled vial was added aryl iodide catalyst **2d** (56.0 mg, 0.10 mmol, 10 mol%) as a solution in CH₂Cl₂ (1.5 mL) followed by pyr·9HF (70% HF, 0.65 mL, 25 mmol HF, 25 eq. HF). Vinylbenzoic acid **8** (148.0 mg, 1.0 mmol, 1.0 eq.) was added as a solution in CH₂Cl₂ (1.0 mL, 0.40 M total concentration). The tube was capped and transferred to a -50 °C cryocool with vigorous stirring (vigorous stirring of the heterogeneous mixture is important to ensure reproducible conversion) at -50 °C for 24 h. After this time, the crude reaction suspension was quenched by being added to a cooled (-78 °C) suspension of basic alumina (2.5 g) in CH₂Cl₂ (5.0 mL). The resulting suspension was warmed to 23 °C and stirred at this temperature for 10 min. The suspension was filtered through a plug of basic alumina, eluting with CH₂Cl₂. The solution was concentrated under reduced pressure. The resulting residue was dry loaded onto celite and purified by column chromatography on silica gel (hexanes:EtOAc 100:0 → 80:20) to afford fluorolactone **7a** as a clear, colorless oil (88 mg, 53%).

69% *ee*, Chiral GC (β-Cyclosil, 60 °C to 180 °C, 10 psi); *t_R*(major) = 29.5 min, *t_R*(minor) = 29.7 min.

Enriched sample:



3-(1-fluoroethyl)isobenzofuran-1(3H)-one 10. To a 1.5 mL glass vial charged with a Teflon PTFE coated stir bar was added (*E*)-2-(prop-1-en-1-yl)benzoic acid **1d** (25 mg, 0.15 mmol, 1.0 eq.) and 2,6-dichloro-1-fluoropyridinium triflate (73 mg, 0.23 mmol, 1.5 eq.). The reaction vial was capped and placed under a nitrogen atmosphere. The vial was charged with CH₂Cl₂ (0.4 mL) and sealed under nitrogen. The vial was placed in a 40 °C heating block with stirring for 20 h. After this time, the crude reaction was dry loaded onto celite and purified by column chromatography on silica gel (hexanes:EtOAc 100:0 → 60:40) to afford fluorolactone **10** as a 1.5:1 mixture of diastereomers as a white solid (25 mg, 93% yield).

¹H-NMR (500 MHz, CDCl₃, 1.5:1 mixture of diastereomers, minor diastereomer marked with *)
 δ 7.90 (d, *J* = 8.0 Hz, 2H), 7.74-7.66 (m, 2H), 7.60-7.52 (m, 3H), 5.51* (dd, *J* = 16.0, 3.5 Hz, 1H), 5.42 (dd, *J* = 10.0, 6.0 Hz, 1H), 5.17-5.02* (m, 1H), 4.75 (dp, *J* = 47.0, 6.0 Hz, 1H), 1.46 (dd, *J* = 23.5, 6.0 Hz, 3H), 1.37* (dd, *J* = 23.5, 6.0 Hz, 3H).

¹³C-NMR (125 MHz, CDCl₃, mixture of diastereomers)
 δ 169.9, 169.8, 150.6, 146.2, 145.6, 140.7, 134.3, 134.2, 129.8, 129.7, 125.9, 125.8, 123.2, 123.1, 89.9 (d, *J* = 173.0 Hz), 88.3 (d, *J* = 173.0 Hz), 81.3 (d, *J* = 28.0 Hz), 80.8 (d, *J* = 25.5 Hz), 16.7 (d, *J* = 22.0 Hz), 15.9 (d, *J* = 22.0 Hz).


^{19}F -NMR (470 MHz, CDCl_3 , 1.5:1 mixture of diastereomers, minor diastereomer marked with *)
 δ -182.8 (m), -188.1* (m)

HRMS (ESI+)

Calculated for $\text{C}_{10}\text{H}_9\text{FO}_2$ (M+H) $^+$: 181.0659
 Found: 181.0660

IR (thin film, cm^{-1})

3082, 2991, 2939, 1767, 1566, 1557, 1414, 1284, 1163, 1137, 1057, 984, 791, 743




4-fluoro-3-methylisochroman-1-one 3. To a 7 mL low-density polyethylene vial with snap cap charged with a Teflon PTFE coated stir bar was added mCPBA (77%, 269 mg, 1.2 mmol, 1.2 eq.). The reaction vial was cooled in a dry ice/acetone bath to <-60 $^\circ\text{C}$. To the cooled vial was added aryl iodide catalyst **2d** (56.0 mg, 0.10 mmol, 10 mol%) as a solution in CH_2Cl_2 (1.5 mL) followed by pyr \cdot 9HF (70% HF, 0.65 mL, 25 mmol HF, 25 eq. HF). (*E*)-2-(prop-1-en-1-yl)benzoic acid **1d** (162.0 mg, 1.0 mmol, 1.0 eq.) was added as a solution in CH_2Cl_2 (1.0 mL, 0.40 M total concentration). The tube was capped and transferred to a -50 $^\circ\text{C}$ cryocool with vigorous stirring (vigorous stirring of the heterogeneous mixture is important to ensure reproducible conversion) at -50 $^\circ\text{C}$ for 24 h. After this time, the crude reaction suspension was quenched by being added to a cooled (-78 $^\circ\text{C}$) suspension of basic alumina (2.5 g) in CH_2Cl_2 (5.0 mL). The resulting suspension was warmed to 23 $^\circ\text{C}$ and stirred at this temperature for 10 min. The suspension was filtered through a plug of basic alumina, eluting with CH_2Cl_2 . The solution was concentrated under reduced pressure. The resulting residue was dry loaded onto celite and purified by column chromatography on silica gel (hexanes:EtOAc 100:0 \rightarrow 80:20) to afford fluorolactone **3** as a white solid (126 mg, 70% yield).

86% *ee*, Chiral HPLC (CHIRALPAK OD-H, 5% isopropanol in hexanes, 1.0 mL/min, λ = 230 nm); t_{R} (major) = 16.8 min, t_{R} (minor) = 22.0 min.

Racemic sample:

DAD1 C, Sig=230,4 Ref=450,100 (CRKDEF_LC 2015-10-27 10-16-59\EMW-561A-IV-247-ME-RAC.D)




Signal 3: DAD1 C, Sig=230,4 Ref=450,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.027	BB	0.4806	6070.55518	191.08333	49.9695
2	21.901	BB	0.5591	6077.95752	165.23271	50.0305

Totals : 1.21485e4 356.31604

Enriched sample:

DAD1 C, Sig=230,4 Ref=450,100 (CRKDEF_LC 2015-10-27 10-16-59\EMW-561A-IV-247-ME.D)




Signal 3: DAD1 C, Sig=230,4 Ref=450,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.818	BB	0.4946	1.58794e4	481.67459	93.0478
2	21.981	BB	0.5369	1186.45020	33.36228	6.9522


Totals : 1.70659e4 515.03687

VIII. Additional substrates

The following substrates gave the fluorolactones as an inseparable mixture of diastereomers (2:1 syn:anti).



The following substrates provided the fluorolactone product in <10% yield.

**IX. X-ray crystallographic data**

X-ray quality crystals of **3** were grown by slow diffusion of pentane into a dissolved solution of the fluorolactone in diethyl ether.

X-Ray Crystallography: Data for a crystal mounted on a diffractometer was collected at 100 K. The intensities of the reflections were collected by means of a Bruker APEX II DUO CCD diffractometer (Cu $K\alpha$ radiation, $\lambda=1.54178$ Å), and equipped with an Oxford Cryosystems nitrogen flow apparatus. The collection method involved 1.0° scans in ω at -30°, -55°, -80°, 30°, 55°, 80° and 115° in 2θ . Data integration down to 0.84 Å resolution was carried out using SAINT V8.34 C (Bruker diffractometer, 2014) with reflection spot size optimisation. Absorption corrections were made with the program SADABS (Bruker diffractometer, 2014). The structure was solved by the Intrinsic Phasing methods and refined by least-squares methods against F^2 using SHELXT-2014 (Sheldrick, 2015) and SHELXL-2014 (Sheldrick, 2015) with OLEX 2 interface (Dolomanov, et al., 2009). Non-hydrogen atoms were refined anisotropically, and hydrogen atoms were allowed to ride on the respective atoms. Crystal data as well as details of data collection and refinement are summarized in Table S1 and geometric parameters are shown in Table S2. The Ortep plots produced with SHELXL-2014 program, and the other drawings were produced with Accelrys DS Visualizer 2.0 (Accelrys, 2007).

Table S1. Experimental details

Crystal data	
Chemical formula	C ₁₀ H ₉ FO ₂
M_r	180.17
Crystal system, space group	Orthorhombic, $P2_12_12_1$
Temperature (K)	100
a, b, c (Å)	4.4860 (2), 6.8678 (3), 27.2439 (11)
V (Å ³)	839.36 (6)
Z	4
Radiation type	Cu $K\alpha$
μ (mm ⁻¹)	0.96
Crystal size (mm)	0.20 × 0.04 × 0.02
Data collection	
Diffractometer	Bruker D8 goniometer with CCD area detector diffractometer
Absorption correction	Multi-scan <i>SADABS</i>
T_{\min}, T_{\max}	0.771, 0.864
No. of measured, independent and observed [$I > 2\sigma(I)$] reflections	18807, 1483, 1431


R_{int}	0.038
$(\sin \theta/\lambda)_{\text{max}}$ (\AA^{-1})	0.595
Refinement	
$R[F^2 > 2\sigma(F^2)], wR(F^2), S$	0.025, 0.065, 1.08
No. of reflections	1483
No. of parameters	119
H-atom treatment	H-atom parameters constrained
$\Delta\rho_{\text{max}}, \Delta\rho_{\text{min}}$ (e \AA^{-3})	0.11, -0.20
Absolute structure	Flack x determined using 532 quotients $[(I^+)-(I^-)]/[(I^+)+(I^-)]$ (Parsons, Flack and Wagner, Acta Cryst. B69 (2013) 249-259).
Absolute structure parameter	-0.03 (4)

Computer programs: *APEX2* v2014.3.0 (Bruker-AXS, 2014), *SAINT* 8.34C (Bruker-AXS, 2014), *SHELXT-2014* (Sheldrick, 2015), *SHELXL2014* (Sheldrick, 2015), Bruker *SHELXTL* (Sheldrick, 2015).

Table S2. Geometric parameters (\AA , $^\circ$)

C1—O2	1.208 (2)	C6—H6	0.9500
C1—O1	1.360 (2)	C7—C8	1.500 (2)
C1—C2	1.482 (2)	C8—F1	1.419 (2)
C2—C3	1.397 (2)	C8—C9	1.511 (2)
C2—C7	1.398 (2)	C8—H8	1.0000
C3—C4	1.382 (3)	C9—O1	1.4540 (19)
C3—H3	0.9500	C9—C10	1.515 (2)
C4—C5	1.390 (3)	C9—H9	1.0000
C4—H4	0.9500	C10—H10A	0.9800
C5—C6	1.388 (2)	C10—H10B	0.9800
C5—H5	0.9500	C10—H10C	0.9800
C6—C7	1.389 (2)		
O2—C1—O1	117.72 (15)	C2—C7—C8	118.61 (15)
O2—C1—C2	124.39 (15)	F1—C8—C7	108.60 (14)
O1—C1—C2	117.80 (14)	F1—C8—C9	109.36 (13)
C3—C2—C7	120.38 (16)	C7—C8—C9	111.25 (13)
C3—C2—C1	118.77 (15)	F1—C8—H8	109.2
C7—C2—C1	120.82 (15)	C7—C8—H8	109.2
C4—C3—C2	119.45 (16)	C9—C8—H8	109.2
C4—C3—H3	120.3	O1—C9—C8	111.17 (13)
C2—C3—H3	120.3	O1—C9—C10	105.78 (13)
C3—C4—C5	120.46 (16)	C8—C9—C10	114.40 (14)

C3—C4—H4	119.8	O1—C9—H9	108.4
C5—C4—H4	119.8	C8—C9—H9	108.4
C6—C5—C4	120.05 (16)	C10—C9—H9	108.4
C6—C5—H5	120.0	C9—C10—H10A	109.5
C4—C5—H5	120.0	C9—C10—H10B	109.5
C5—C6—C7	120.24 (16)	H10A—C10—H10B	109.5
C5—C6—H6	119.9	C9—C10—H10C	109.5
C7—C6—H6	119.9	H10A—C10—H10C	109.5
C6—C7—C2	119.41 (15)	H10B—C10—H10C	109.5
C6—C7—C8	121.97 (15)	C1—O1—C9	119.52 (13)
O2—C1—C2—C3	8.5 (3)	C1—C2—C7—C8	-0.6 (2)
O1—C1—C2—C3	-174.91 (15)	C6—C7—C8—F1	-87.16 (19)
O2—C1—C2—C7	-169.40 (17)	C2—C7—C8—F1	92.15 (17)
O1—C1—C2—C7	7.2 (2)	C6—C7—C8—C9	152.44 (16)
C7—C2—C3—C4	-0.5 (3)	C2—C7—C8—C9	-28.3 (2)
C1—C2—C3—C4	-178.43 (15)	F1—C8—C9—O1	-69.37 (16)
C2—C3—C4—C5	-0.3 (3)	C7—C8—C9—O1	50.59 (19)
C3—C4—C5—C6	0.9 (3)	F1—C8—C9—C10	50.36 (19)
C4—C5—C6—C7	-0.6 (3)	C7—C8—C9—C10	170.32 (14)
C5—C6—C7—C2	-0.3 (3)	O2—C1—O1—C9	-164.91 (15)
C5—C6—C7—C8	179.03 (16)	C2—C1—O1—C9	18.2 (2)
C3—C2—C7—C6	0.8 (3)	C8—C9—O1—C1	-47.65 (19)
C1—C2—C7—C6	178.68 (15)	C10—C9—O1—C1	-172.38 (14)
C3—C2—C7—C8	-178.49 (15)		



Three-dimensional supramolecular architecture viewed along the *a*-axis direction.

X-ray quality crystals of **7c** were grown by slow evaporation from a saturated solution of the lactone in diethyl ether.

X-Ray Crystallography: Data for a crystal mounted on a diffractometer was collected at 100 K. The intensities of the reflections were collected by means of a Bruker APEX II DUO CCD diffractometer (Cu_{Kα} radiation, $\lambda=1.54178$ Å), and equipped with an Oxford Cryosystems nitrogen flow apparatus. The collection method involved 1.0° scans in ω at -30°, -55°, -80°, 30°, 55°, 80° and 115° in 2θ . Data integration down to 0.84 Å resolution was carried out using SAINT V8.34 C (Bruker diffractometer, 2014) with reflection spot size optimisation. Absorption corrections were made with the program SADABS (Bruker diffractometer, 2014). The structure was solved by the Intrinsic Phasing methods and refined by least-squares methods against F^2 using SHELXT-2014 (Sheldrick, 2015) and SHELXL-2014 (Sheldrick, 2015) with OLEX 2 interface (Dolomanov, et al., 2009). Non-hydrogen atoms were refined anisotropically, and hydrogen atoms were allowed to ride on the respective atoms. Crystal data as well as details of data collection and refinement are summarized in Table S3 and geometric parameters are shown in Table S4. The Ortep plots produced with SHELXL-2014 program, and the other drawings were produced with Accelrys DS Visualizer 2.0 (Accelrys, 2007).

Table S3. Experimental details

Crystal data	
Chemical formula	C ₁₂ H ₁₂ ClFO ₂
M_r	242.67
Crystal system, space group	Mon ^o Clinic, C2
Temperature (K)	100
a, b, c (Å)	21.6152 (6), 4.3127 (1), 14.1504 (4)
β (°)	123.3915 (9)
V (Å ³)	1101.35 (5)
Z	4
Radiation type	Cu $K\alpha$
μ (mm ⁻¹)	3.06
Crystal size (mm)	0.26 × 0.14 × 0.12
Data collection	
Diffractometer	Bruker D8 goniometer with CCD area detector diffractometer
Absorption correction	Multi-scan <i>SADABS</i>
T_{\min}, T_{\max}	0.681, 0.806
No. of measured, independent and	12210, 1747, 1734


observed [$I > 2\sigma(I)$] reflections	
R_{int}	0.027
$(\sin \theta/\lambda)_{\text{max}}$ (\AA^{-1})	0.596
Refinement	
$R[F^2 > 2\sigma(F^2)]$, $wR(F^2)$, S	0.022, 0.059, 1.08
No. of reflections	1747
No. of parameters	145
No. of restraints	1
H-atom treatment	H-atom parameters constrained
$\Delta\rho_{\text{max}}$, $\Delta\rho_{\text{min}}$ (e \AA^{-3})	0.17, -0.21
Absolute structure	Flack x determined using 648 quotients $[(I^+)-(I^-)]/[(I^+)+(I^-)]$ (Parsons, Flack and Wagner, Acta Cryst. B69 (2013) 249-259).
Flack (x) parameter	-0.004 (12)
Hooft parameter	0.011(6)

Computer programs: *APEX2* v2014.3.0 (Bruker-AXS, 2014), *SAINT* 8.34C (Bruker-AXS, 2014), *SHELXT-2014* (Sheldrick, 2015), *SHELXL2014* (Sheldrick, 2015), Bruker *SHELXTL* (Sheldrick, 2015).

Table S4. Geometric parameters (\AA , $^\circ$)

C1—O2	1.209 (3)	C8—C9	1.509 (3)
C1—O1	1.358 (2)	C8—H8	1.0000
C1—C2	1.482 (3)	C9—O1	1.458 (3)
C2—C3	1.394 (3)	C9—C10	1.517 (3)
C2—C7	1.396 (3)	C9—H9	1.0000
C3—C4	1.382 (3)	C10—C11	1.528 (3)
C3—H3	0.9500	C10—H10A	0.9900
C4—C5	1.388 (3)	C10—H10B	0.9900
C4—H4	0.9500	C11—C12	1.516 (3)
C5—C6	1.390 (3)	C11—H11A	0.9900
C5—H5	0.9500	C11—H11B	0.9900
C6—C7	1.385 (3)	C12—C11	1.810 (2)
C6—H6	0.9500	C12—H12A	0.9900
C7—C8	1.497 (3)	C12—H12B	0.9900
C8—F1	1.422 (3)		
O2—C1—O1	117.85 (19)	C9—C8—H8	109.6
O2—C1—C2	124.35 (18)	O1—C9—C8	110.67 (17)
O1—C1—C2	117.77 (19)	O1—C9—C10	107.25 (17)
C3—C2—C7	119.7 (2)	C8—C9—C10	113.68 (17)
C3—C2—C1	119.68 (19)	O1—C9—H9	108.4

C7—C2—C1	120.62 (18)	C8—C9—H9	108.4
C4—C3—C2	119.9 (2)	C10—C9—H9	108.4
C4—C3—H3	120.1	C9—C10—C11	112.78 (17)
C2—C3—H3	120.1	C9—C10—H10A	109.0
C3—C4—C5	120.34 (19)	C11—C10—H10A	109.0
C3—C4—H4	119.8	C9—C10—H10B	109.0
C5—C4—H4	119.8	C11—C10—H10B	109.0
C4—C5—C6	120.1 (2)	H10A—C10—H10B	107.8
C4—C5—H5	120.0	C12—C11—C10	113.28 (18)
C6—C5—H5	120.0	C12—C11—H11A	108.9
C7—C6—C5	119.8 (2)	C10—C11—H11A	108.9
C7—C6—H6	120.1	C12—C11—H11B	108.9
C5—C6—H6	120.1	C10—C11—H11B	108.9
C6—C7—C2	120.17 (19)	H11A—C11—H11B	107.7
C6—C7—C8	122.11 (19)	C11—C12—Cl1	111.88 (16)
C2—C7—C8	117.71 (19)	C11—C12—H12A	109.2
F1—C8—C7	108.69 (17)	Cl1—C12—H12A	109.2
F1—C8—C9	108.46 (18)	C11—C12—H12B	109.2
C7—C8—C9	110.93 (17)	Cl1—C12—H12B	109.2
F1—C8—H8	109.6	H12A—C12—H12B	107.9
C7—C8—H8	109.6	C1—O1—C9	120.29 (17)
O2—C1—C2—C3	14.7 (4)	C2—C7—C8—F1	86.3 (2)
O1—C1—C2—C3	-167.4 (2)	C6—C7—C8—C9	147.2 (2)
O2—C1—C2—C7	-163.7 (2)	C2—C7—C8—C9	-32.9 (3)
O1—C1—C2—C7	14.2 (3)	F1—C8—C9—O1	-66.2 (2)
C7—C2—C3—C4	-0.7 (3)	C7—C8—C9—O1	53.1 (2)
C1—C2—C3—C4	-179.1 (2)	F1—C8—C9—C10	54.6 (2)
C2—C3—C4—C5	0.1 (4)	C7—C8—C9—C10	173.92 (19)
C3—C4—C5—C6	0.3 (4)	O1—C9—C10—C11	-71.4 (2)
C4—C5—C6—C7	-0.1 (4)	C8—C9—C10—C11	166.0 (2)
C5—C6—C7—C2	-0.5 (4)	C9—C10—C11—C12	178.7 (2)
C5—C6—C7—C8	179.5 (2)	C10—C11—C12—Cl1	56.7 (3)
C3—C2—C7—C6	0.9 (3)	O2—C1—O1—C9	-172.7 (2)
C1—C2—C7—C6	179.3 (2)	C2—C1—O1—C9	9.2 (3)
C3—C2—C7—C8	-179.0 (2)	C8—C9—O1—C1	-43.0 (3)
C1—C2—C7—C8	-0.7 (3)	C10—C9—O1—C1	-167.49 (17)
C6—C7—C8—F1	-93.7 (2)		



Three-dimensional supramolecular architecture viewed along the *b*-axis direction.

X-ray quality crystals of **7f** were grown by slow evaporation from a saturated solution of the lactone in diethyl ether.

X-Ray Crystallography: Data for a crystal mounted on a diffractometer was collected at 100 K. The intensities of the reflections were collected by means of a Bruker APEX II DUO CCD diffractometer ($\text{CuK}\alpha$ radiation, $\lambda=1.54178$ Å), and equipped with an Oxford Cryosystems nitrogen flow apparatus. The collection method involved 1.0° scans in ω at -30° , -55° , -80° , 30° , 55° , 80° and 115° in 2θ . Data integration down to 0.84 Å resolution was carried out using SAINT V8.34 C (Bruker diffractometer, 2014) with reflection spot size optimization. Absorption corrections were made with the program SADABS (Bruker diffractometer, 2014). The structure was solved by the Intrinsic Phasing methods and refined by least-squares methods against F^2 using SHELXT-2014 (Sheldrick, 2015) and SHELXL-2014 (Sheldrick, 2015) with OLEX 2 interface (Dolomanov, et al., 2009). Non-hydrogen atoms were refined anisotropically, and hydrogen atoms were allowed to ride on the respective atoms. Crystal data as well as details of data collection and refinement are summarized in Table S5 and geometric parameters are shown in Table S6. The Ortep plots produced with SHELXL-2014 program, and the other drawings were produced with Accelrys DS Visualizer 2.0 (Accelrys, 2007).

Table S5. Experimental details

Crystal data	
Chemical formula	$\text{C}_{11}\text{H}_{11}\text{FO}_3$
M_r	210.20
Crystal system, space group	Monoclinic, $P2_1$
Temperature (K)	100

a, b, c (Å)	4.5174 (2), 6.8284 (4), 15.9328 (8)
β (°)	92.4936 (17)
V (Å ³)	491.01 (4)
Z	2
Radiation type	Cu $K\alpha$
μ (mm ⁻¹)	0.98
Crystal size (mm)	0.18 × 0.10 × 0.08
Data collection	
Diffractometer	Bruker D8 goniometer with CCD area detector diffractometer
Absorption correction	Multi-scan <i>SADABS</i>
T_{\min}, T_{\max}	0.765, 0.864
No. of measured, independent and observed [$I > 2\sigma(I)$] reflections	12027, 1628, 1588
R_{int}	0.034
$(\sin \theta/\lambda)_{\text{max}}$ (Å ⁻¹)	0.596
Refinement	
$R[F^2 > 2\sigma(F^2)], wR(F^2), S$	0.033, 0.086, 1.04
No. of reflections	1628
No. of parameters	138
No. of restraints	1
H-atom treatment	H-atom parameters constrained
$\Delta\rho_{\text{max}}, \Delta\rho_{\text{min}}$ (e Å ⁻³)	0.19, -0.15
Absolute structure	Classical Flack method preferred over Parsons because s.u. lower.
Absolute structure parameter	0.0 (2)


Computer programs: *APEX2* v2014.3.0 (Bruker-AXS, 2014), *SAINT* 8.34C (Bruker-AXS, 2014), *SHELXT-2014* (Sheldrick, 2015), *SHELXL2014* (Sheldrick, 2015), Bruker *SHELXTL* (Sheldrick, 2015).

Table S6. Geometric parameters (Å, °)

C1—O2	1.205 (3)	C8—F1	1.419 (3)
C1—O1	1.358 (3)	C8—C9	1.505 (4)
C1—C2	1.481 (3)	C8—H8	1.0000
C2—C3	1.394 (3)	C9—O1	1.449 (3)
C2—C7	1.398 (3)	C9—C10	1.514 (3)
C3—C4	1.389 (4)	C9—H9	1.0000

C3—H3	0.9500	C10—O3	1.413 (3)
C4—C5	1.386 (4)	C10—H10A	0.9900
C4—H4	0.9500	C10—H10B	0.9900
C5—C6	1.387 (4)	C11—O3	1.418 (3)
C5—H5	0.9500	C11—H11A	0.9800
C6—C7	1.392 (4)	C11—H11B	0.9800
C6—H6	0.9500	C11—H11C	0.9800
C7—C8	1.501 (3)		
O2—C1—O1	117.9 (2)	F1—C8—H8	109.4
O2—C1—C2	124.3 (2)	C7—C8—H8	109.4
O1—C1—C2	117.77 (19)	C9—C8—H8	109.4
C3—C2—C7	120.4 (2)	O1—C9—C8	111.31 (19)
C3—C2—C1	118.9 (2)	O1—C9—C10	105.29 (19)
C7—C2—C1	120.7 (2)	C8—C9—C10	115.1 (2)
C4—C3—C2	119.6 (2)	O1—C9—H9	108.3
C4—C3—H3	120.2	C8—C9—H9	108.3
C2—C3—H3	120.2	C10—C9—H9	108.3
C5—C4—C3	120.1 (2)	O3—C10—C9	106.67 (19)
C5—C4—H4	119.9	O3—C10—H10A	110.4
C3—C4—H4	119.9	C9—C10—H10A	110.4
C4—C5—C6	120.5 (2)	O3—C10—H10B	110.4
C4—C5—H5	119.8	C9—C10—H10B	110.4
C6—C5—H5	119.8	H10A—C10—H10B	108.6
C5—C6—C7	120.0 (2)	O3—C11—H11A	109.5
C5—C6—H6	120.0	O3—C11—H11B	109.5
C7—C6—H6	120.0	H11A—C11—H11B	109.5
C6—C7—C2	119.4 (2)	O3—C11—H11C	109.5
C6—C7—C8	122.2 (2)	H11A—C11—H11C	109.5
C2—C7—C8	118.5 (2)	H11B—C11—H11C	109.5
F1—C8—C7	108.66 (19)	C1—O1—C9	118.96 (18)
F1—C8—C9	109.47 (19)	C10—O3—C11	111.86 (19)
C7—C8—C9	110.56 (19)		
O2—C1—C2—C3	9.2 (4)	C6—C7—C8—F1	-88.5 (3)
O1—C1—C2—C3	-173.6 (2)	C2—C7—C8—F1	91.5 (2)
O2—C1—C2—C7	-168.6 (2)	C6—C7—C8—C9	151.3 (2)
O1—C1—C2—C7	8.6 (3)	C2—C7—C8—C9	-28.6 (3)
C7—C2—C3—C4	-0.9 (4)	F1—C8—C9—O1	-67.4 (2)
C1—C2—C3—C4	-178.7 (2)	C7—C8—C9—O1	52.3 (3)
C2—C3—C4—C5	0.2 (4)	F1—C8—C9—C10	52.3 (2)
C3—C4—C5—C6	0.7 (4)	C7—C8—C9—C10	171.96 (19)
C4—C5—C6—C7	-0.9 (4)	O1—C9—C10—O3	-168.78 (19)
C5—C6—C7—C2	0.2 (4)	C8—C9—C10—O3	68.3 (3)
C5—C6—C7—C8	-179.8 (2)	O2—C1—O1—C9	-164.8 (2)
C3—C2—C7—C6	0.7 (4)	C2—C1—O1—C9	17.8 (3)
C1—C2—C7—C6	178.5 (2)	C8—C9—O1—C1	-49.0 (3)
C3—C2—C7—C8	-179.4 (2)	C10—C9—O1—C1	-174.34 (19)

C1—C2—C7—C8	-1.6 (3)	C9—C10—O3—C11	175.7 (2)
-------------	----------	---------------	-----------










Three-dimensional supramolecular architecture viewed along the *a*-axis direction.



References for X-ray crystallography data:





- [1] Bruker AXS APEX II, Bruker AXS, Madison, Wisconsin, **2014**.
- [2] Accelrys DS Visualizer v2.0.1, Accelrys Software, Inc., **2007**.
- [3] G. M. Sheldrick, *Acta Cryst.* **2015**, *A71*, 3-8.
- [4] G. M. Sheldrick, *Acta Cryst.* **2015**, *C71*, 3-8.
- [5] O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann *J. Appl. Cryst.* **2009**, *42*, 339-341.


X. NMR spectra















4b





4b











4c





4c









4e





4e











4f





4f











4h





4h









4i








4i













4i


















4I





4I







4m





4m














4n









4n




















































































































































6c





6c
















6e







6e























































































































SI-11



SI-11





-
- ¹ Pangborn, A.B.; Giardello, M.A; Grubbs, R.H.; Rosen, R.K.; Timmers, F.J. *Organometallics* **1996**, *15*, 1518.
- ² Still, W.C.; Kahn, M.; Mitra, A.; *J. Org. Chem.* **1978**, *43*, 2923.
- ³ Tsujiyama, S.; Suzuki, K. *Org. Synth.* **2007**, *84*, 272-284.
- ⁴ Fujita, M.; Mori, K.; Shimogaki, M.; Sugimura, T. *Org. Lett.* **2012**, *14*, 1294-1297.
- ⁵ Emer, E.; Pfeifer, L.; Brown, J. M.; Gouverneur, V. *Angew. Chem. Int. Ed.* **2014**, *53*, 4181-4185.
- ⁶ Mitra, P.; Shome, B.; De, S. R.; Sarkar, A.; Mal, D. *Org. Biomol. Chem.* **2012**, *10*, 2742-2752.
- ⁷ Fujita, M.; Yoshida, Y.; Miyata, K.; Wakisaka, A.; Sugimura, T. *Angew. Chem. Int. Ed.* **2010**, *49*, 7068-7071.